

Connecting the World for a Cause



dcvmmn
2015



WELCOME NOTE FROM THE PRESIDENT

Dear Members and Friends,

In 2015 DCMN has continued to grow.

We are happy to renew our commitment to support global initiatives to achieve and maintain a world free of vaccine preventable diseases for future generations.

We have now 45 members joined the Network, it has further grown from 41 members in 2014. Please accept our heartfelt welcome to our new DCMN members, and we encourage them to fully contribute in this network.

The friends of DCMN have further grown as well, with new corporate Partners and donors supporting our efforts to build the tailored training programs. These programs are designed to strengthen the quality management systems of manufacturers in developing countries, improving prequalification of needed vaccines to protect people against infectious diseases globally.

This is a nascent effort to generate new synergies and strong cooperation between developing countries industry and governments to reinvigorate manufacturers from developing regions to continue sharing the responsibility of preventing the spread of infectious diseases worldwide through improved supply of needed vaccines.

Together we gradually built an incredible global community of people who have entrepreneurial thinking to make changes happen. Our Network is serving to build a society where access to preventive vaccination will be fully met everywhere. The demand for local vaccines generates local employment bringing to full potential the multiple skills of everyone, for all levels of ability.

I am proud of vaccine manufacturers from developing countries!

Sincerely,

A handwritten signature in blue ink, appearing to read 'Mahendra'.

Mahendra Suhardono
DCMN President

EXECUTIVE COMMITTEE MEMBERS



Mr. Mahendra Suhardono
President
Bio Farma, Indonesia



Mr. Rajender Kumar Suri
Vice President
Panacea Biotech Limited, India



Dr. Akira Homma
Treasurer
Bio-Manguinhos (Fiocruz), Brazil



Mr. Rayasam Prasad
Biological E. Limited, India



Ms. Meng Li
China National Biotec Group Co.Ltd., China



Mr. Patrick Tippoo
The Biovac Institute, South Africa



Mr. Juliman
GAVI Board Alternate
Bio Farma, Indonesia



Dr. Steven Gao
Xiamen Innovax Biotech Co. Ltd., China



Mr. Adar Poonawalla
GAVI Board Representative
Serum Institute of India Ltd., India



Dr. Sonia R Pagliusi
Executive Secretary
DCVMN International

Member Organizations' Geographical Presence

	Argentina
	Bangladesh
	Brazil
	Cuba
	Egypt
	India
	Indonesia
	IR of Iran
	Mexico
	P.R. China
	Republic of Korea
	Saudi Arabia
	South Africa
	Taiwan
	Thailand
	Vietnam



Name of the company : **Arab Company for Pharmaceutical Products (Arabio)**
 Head of Institution : **Dr. Majed Saeed Bahatheq** (Arabio CEO)
 Established : **Arabio is a limited liability company established in 2005**
 Location : **Saudi Arabia**

Overview of the company

Arabio is a biopharmaceutical company specialized in human vaccines, and other biopharmaceuticals.

It is the first biopharmaceutical company in the Gulf Cooperation Council (GCC). The size and scope of activities intended to be made in Arabio would make Arabio the first biological company of its kind in the Middle East.



Arabio aims to bring to the markets of the Middle East, North Africa, and high quality products that comply with the international quality standards.

Arabio has production lines of pre-filled syringes, liquid vials and lyophilized vials from the best global machines suppliers to make high quality products and meet cGMP & international standards.

Description of ARABIO capabilities

- Biological sterile manufacturing
- PFS and vial filling
- PFS and vial blister packaging

Arabio Partners:

1. Novartis Vaccine
2. GSK Vaccines
3. InterVax Vaccine
4. BioFarma, Indonesia
5. AbbVie
6. J & J
7. Bioton, Poland

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Cervical Cancer HPV		PFS	
Hepatitis B Pead		Vial	
Hepatitis A Pead		Vial	
Hexa vaccine (DTaP, Polio, HiB, HepB)		PFS	
(DTaP, HiB)		PFS	
(DTaP)		PFS	
(DTaP)		PFS	
Rota Virus		PFS	
Pneumococcal		PFS	
(DTaP) adult		PFS	
Hep. B adult		Vial	
Hep. A adult		Vial	
Meningococcal conjugate ACWY vaccine		Vial	
Penta Vaccine (DTwP, HiB, HepB)		Vial	
Sesonal Influenza Vaccine		PFS	
BCG		Amp	
Tuberculin		Vial	
Oral Polio Vaccine (trivalent) 10 ds		Vial	
Tetanus Toxoid (TT) vaccine 10 ds		Vial	
Diphtheria-Tetnus (DT) Pediatric vaccine		Vial	
Humira		PFS	
Survanta		Vial	
Sevoflurane		Bottel	
Resperdal Consta		Vial	
Velcade		Vial	

Future Product Pipe Line

- MMR
- Varicella
- MMRV
- Dengue Fever vaccine
- RSV

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

Vaccines:

- MMR
- Varicella
- MMRV
- Dengue Fever vaccine
- RSV

Biological Products:

- Insulin
- Protein kinas inhibitor
- Blood coagulation
- Anti TNF products
- Hormonal contraceptive
- Heparins
- Growth hormones
- Erythropoietin
- MAB antineoplastic
- Interferons

Contact Details

Name of contact person	: Tarek Ibrahim Mahmoud	Phone	: +966-11-4615533
Address	: Khuris Road, Khuris Commercial Center Opp. King Fahad Medical City P.O Box 63243, Riyadh-11516, KSA		
Factory	: Al Umrah Dist Makkah Industrial Zone, P.O. Box 20355, Makkah-21955, KSA.	Mobile	: +966-56-5933303
City	: Riyadh	Fax	: +966-11-4633729
State	:	email	: tarekibrahim@arabio.com
Location	: Saudi Arabia	Website	: www.arabio.com
Postal code	: 11516		





Name of the company : **Beijing Minhai Biotechnology Co., Ltd**

Head of Institution : **Dr. Zheng Haifa**

Established : **2004**

Location : **P.R. China**

Overview of the company

Beijing Minhai Biotechnology Co.,Ltd.(referred to as“Minhai”) is a modern biotechnology enterprise specialized in vaccine R&D, production and distribution. Minhai's mission is to provide safe, stable and affordable vaccines; increase immunization coverage, reduce the incidence of infectious disease and mortality; protect human health.

Minhai was founded in June 2004, with a registered capital of 200 million RMB and a total asset of 800 million RMB, at No.35, Simiao Road, Bio-medicine Industry Park in Daxing District, Beijing, which has a leading R&D center and a modern vaccine manufacturing site composed of over 60,000 m² GMP compliant workshops, equipped with advanced large-scale bacteria vaccine production line and virus vaccine production line.

Until 2015, there are three commercialized vaccine products in China, including Hib conjugate vaccine, MR vaccine and DTaP-Hib vaccine. DTaP-Hib vaccine, which is independently developed by Minhai, is the first domestic quadrivalent vaccine.

There are over 20 vaccines in Minhai's pipeline (from pre-clinical trial to NDA), including pneumococcal conjugate vaccine, HDCV rabies vaccine, sabin IPV and meningitis conjugate vaccine etc.



In the meantime of developing novel vaccines, Minhai initiated international registration and accelerated the process of export. From 2013, Minhai has started the registration of three marketed products in more than 10 countries including India, Russia and the Philippines, and initiated WHO prequalification preparation. Minhai is enlarging multi-angle, multi-level international collaboration, and extensively promote globalization strategy.

Minhai is collaborating and competing with world class vaccine enterprises, working hard to share Minhai's safe, stable and affordable vaccines with all human beings around the world.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hib	Hemophilus Influenae type b vaccine	Vial	0.5 ml
DTaP-Hib	Diphtheria, Tetanus, acellular Pertussis, and Hemophilus Influenae type b combined vaccine	Vial	0.5 ml+0.5ml
MR	Measles and Rubella combined vaccine	Vial	Lyophilized

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
DTaP-Hib-sIPV Combined Vaccine					
Tuberculosis					
Component DTP					
15-valent PCV					
ACYW135 MPV					
ACYW135 MCV					
13-valent PCV					
Hib (Lyo)					
Cholera(Oral)					
23-valent PPV				NDA	
DTaP					
5-valent Rotavirus					
sIPV					
Zoster					
H7N9 influenza					
HDCV rabies (purified)					
Varicella					
Inactivated HepA					
Influenza (Split)					
HDCV Rabies (non-purified)					
Quadrivalent HPV					
HSV					
EV71					
H1N1 Influenza					
Group B Meningitis					
Recombinant HepB (Hansenula)					

Areas of Interest for Collaboration

- Technology Transfer
- Vaccine Co-development
- Overseas Registration and Distribution

Contact Details

Name of contact person

: Zhang Qian

Address

: 35 Simiao Road, Bio-medicine Industry Park
Daxing District

City

: Beijing

State

:

Location

: P.R. China

Postal code

: 102600

Phone

: +86 10 59613590

Mobile

:

Fax

: +86 10 59613655

email

: minhaigjhz@126.com

Website

: www.biominhai.com





Name of the company : **Beijing Tiantan Biological Products Co., Ltd.**

Head of Institution : **Mr. Zeng Lingbing**, General Manager

Established : **1998**

Location : **P.R. China**

Overview of the company

Beijing Tiantan Biological Products Co., Ltd. (abbreviated as TiantanBio) is a state-controlled listed corporation for high technology, engaging in research, manufacturing and marketing of biological products such as vaccines, blood derivatives and diagnostic kits. It's a spin-off company from National Vaccine & Serum Institute (NVI) and became public listed in the China Shanghai Stock Exchange since 1998. TiantanBio owns several subsidiary companies, such as Chengdu Rongsheng Pharmaceutical Co., Ltd., Changchun Keygen Biological Products Co., Ltd., and several serum sampling companies. Now China National Biotec Group Company Limited is its controlling shareholder. At present, TiantanBio has more than 2200 staffs, including a batch of influential senior technical personnel working in the field of R&D, manufacturing and quality assurance.



TiantanBio has the most complete portfolio of vaccines in the National Immunization Program. The leading products are Hepatitis B Vaccine (Yeast Recombinant), Attenuated Measles Mumps and Rubella Combined Vaccine Live, Attenuated Measles and Rubella Combined Vaccine Live, Diphtheria Tetanus and Acellular Pertussis Combined Vaccine Adsorbed, Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell) Live, Japanese Encephalitis Vaccine (Vero Cell) Inactivated, Attenuated Freeze-dried Varicella Vaccine Live, Influenza Vaccine (Spilt Virion) Inactivated, H1N1 Influenza A Vaccine (Spilt Virion) Inactivated, Human Albumin, Human Immunoglobulin (pH4) for Intravenous Injection, Human Immunoglobulin and so on.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
TEMREVAC	Hepatitis B Vaccine made by Recombinant DNA Techniques in Yeast	Ampoule	0.5ml , 1.0ml
	Yellow Fever Vaccine, Live	Vial	6 doses 0.3ml
	Influenza Vaccine (Split Virion), Inactivated	Injector /Vial	0.5ml
RUBEVAC	Rubella vaccine, Live (Human Diploid Cell)	Vial	0.5ml
	Japanese Encephalitis Vaccine (Vero Cell), Inactivated	Vial	0.5ml
	Measles, Mumps and Rubella Combined Vaccine, Live (M/R/MR/MMR)	Vial	0.5ml
	Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell), Live	Pill	1g
Shengdoushi	Freeze-dried Live Attenuated Varicella Vaccine	Vial	0.5ml
Trivac	Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed (DTaP)	Ampoule	0.5ml
	Group A Meningococcal Polysaccharide Vaccine	Vial	10 doses 300µg
	Typhoid Vi Polysaccharide Vaccine	Ampoule	2 doses 1 ml
	Anti-human T Lymphocyte Rabbit Immunoglobulin	Vial	25mg
	Human Hepatitis B Immunoglobulin	Vial	100IU
	Human Albumin	Vial	10ml/25ml/50ml
	Human Immunoglobulin(pH4) for intravenous Injection	Vial	25ml/50ml
	Human Tetanus Immunoglobulin	Vial	250IU

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Recombinant Interferon β 1b					
Meningococcal ACWY Vaccine (Polysaccharide)					
Meningococcal A+C Conjugate Vaccine					
MMR+ Varicella Vaccine					
Pertussis component vaccine					
Inactivated Poliomyelitis Vaccine					

Areas of Interest for Collaboration

- Combined Vaccine
- Large-scale Production Technology
- Quality System
- New Antigen

Contact Details

Name of contact person : **Ms. ZHANG Yucui**

Address : **No. 4 Sanjianfang Nanli, Chaoyang District,
Beijing 100024, P.R.C.**

City : **Beijing**

State :

Location : **P.R. China**

Postal code: **100024**

Phone : **+8610-65762911-2543**

Mobile : **+86-13911757012**

Fax : **+8610-65792747**

email : **ttbiozyc@yahoo.com.cn**

Website: **<http://www.tiantanbio.com>**



Name of the company : **Bharat Biotech International Limited**

Head of Institution : **Dr. Krishna M. Ella**, Chairman & Managing Director


Established : **1996**

Location : **India**

Overview of the company

Bharat Biotech International Limited (BBIL) was incorporated in 1996 at Hyderabad. BBIL was founded by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella, to establish a knowledge base for new vaccine development in the developing world. BBIL has a vision to develop novel vaccines against neglected diseases of the developing world. Dr. V. Krishna Mohan, Executive Director, heads the day to day operations.

BBIL is a multi-dimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and bio-therapeutics. BBIL is providing affordable, global health care solutions at global quality standards. The company pioneered manufacture of the world's first Cesium chloride- free Hepatitis-B vaccine with HIMAX®



technology, a novel purification matrix patented globally. BBIL has successfully manufactured preservative -free Hep-B and Hib vaccines. BBIL is the first Indian company to obtain a global patent for a biotech molecule r-LYSOSTAPHIN, to fight Staphylococcal infections. BBIL was certified by KFDA for the manufacture of parenterals. BBIL has a strong focus on innovation and intellectual property rights, with a belief in "developing our own IPR and not violating IPR". Typhoid Vi polysaccharide Conjugate and Inactivated Japanese Encephalitis vaccines of BBIL have been granted commercial licensure in 2013. Rotavirus Vaccine was granted commercial licensure in 2014. Trivalent and Bivalent Oral Polio Vaccines of BBIL are Pre-Qualified by WHO. The focus on neglected diseases is unparalleled at BBIL. Vaccines against malaria, chikungunya, human papiloma, MRSA strains and salmonellosis are in the pipeline.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Revac-B+	Hepatitis B Vaccine, rDNA (Pichia pastoris), 20 µg of HBsAg/1.0 mL (Adult)	Vial	0.5 mL, 1.0 mL, 2.5 mL, 3.0 mL, 5.0 mL, 10.0 mL
Revac-B mcf	Hepatitis B Vaccine, rDNA (Pichia pastoris) Thiomersal Free, 20 µg of HBsAg/1.0 mL (Adult)	Vial	0.5 mL, 1.0 mL
INDIRAB	Rabies Vaccine Vero Cell-Derived; Pitman-Moore strain of Rabies virus Potency ≥ 2.5 I.U./0.5 mL	Vial	0.5 mL, 1.0 mL
TYPBAR	Vi Capsular Polysaccharide Typhoid Vaccine Vi Capsular polysaccharide of S. typhi (Ty2 strain) 25 µg/ 0.5 mL	Vial	0.5 mL, 2.5 mL
HNVAC	H1N1 Pandemic 2009 Flu Vaccine	Vial	0.5 mL
Typbar TCV	Typhoid Vi Capsular Polysaccharide TT Conjugate Vaccine	Vial/ PFS	0.5 mL, 2.5 mL
JENVAC	Japanese Encephalitis Vaccine, Inactivated	Vial	0.5 mL, 2.5 mL
ROTAVAC	Rotavirus Vaccine, Live Attenuated, Oral	Vial	0.5 mL, 2.5 mL, 5.0 mL
BIOPOLIO	Trivalent Oral Poliomyelitis Vaccine Live, Attenuated (Sabin) 0.1 mL (2 drops)	Vial	2 mL, 1 mL
BIOPOLIO M1	Monovalent Oral Poliomyelitis Vaccine Type 1 Live, Attenuated (Sabin) 0.1 mL	Vial	2 mL, 1.0 mL
BIOPOLIO M3	Monovalent Oral Poliomyelitis Vaccine Type 3 Live, Attenuated (Sabin) 0.1 mL	Vial	2 mL, 1.0 mL
BIOPOLIO 1&3	Bivalent Oral Poliomyelitis Vaccine Type 1&3 (Sabin) 0.1 mL	Vial	2.0 mL, 1.0 mL
ComVac4-HB (DPT+Hep-B)	Diphtheria, Pertussis (w), Tetanus, Hepatitis-B Vaccine (Quadrivalent Vaccine) 0.5 mL	Vial	0.5 mL, 2.5 mL, 5.0 mL
ComVac5 (DPT+Hep B+Hib)	Diphtheria, Pertussis (w), Tetanus, Hepatitis-B & Haemophilus influenzae Vaccine, (Pentavalent Vaccine) 0.5 mL	Vial	0.5 mL, 2.5 mL, 5.0 mL
ComVac3	Diphtheria Tetanus Pertussis Vaccine (DTP Vaccine) 0.5 mL	Vial	0.5 mL, 2.5 mL, 5.0 mL
REGEN-D 150	r- Human Epidermal Growth Factor Gel 150 µg/gm	Tube	7.5g, 15g, 30g, 60g, 150g
REGEN-D 60	r- Human Epidermal Growth Factor Gel 60 µg/gm	Tube	7.5g, 15g, 30g, 60g, 150g
BIOGIT / FloraNorm	Saccharomyces boulardii (Granular) 250 mg, oral	Sachet	Sachet
BioHib	Purified capsular polysaccharide of Hib [covalently bound to 20-40 µg Tetanus toxoid (PRP-TT)] 10 µg	PFS	0.5 mL

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Recombinant Human Growth Hormone					
Recombinant Human Serum Albumin					
Recombinant Parathyroid Hormone					
THR-100 [Recombinant Staphylokinase]					
Lysostaphin for S.aureus infections, topical					
Rotavirus Vaccine Candidate 116E					Launched in March 2015
Malaria Vaccine Candidate -1 (r-PvRII)					
Malaria Vaccine Candidate -2 (PfMSP-19)					
Malaria Vaccine Candidate -3 (PfF2)					

Areas of Interest for Collaboration

- Development of Novel vaccines for Neglected diseases
- Development of novel adjuvants
- Development of novel therapeutics

Contact Details

Name of contact person	: Mr. Sai D. Prasad, President	Phone	: +91 40 2348 0567
Address	: Bharat Biotech Genome Valley	Mobile	: +91 9848887866
City	: Hyderabad	Fax	: +91 40 2348 0560
State	: Telangana	email	: prasadsd@bharatbiotech.com
Location	: India	Website	: www.bharatbiotech.com
Postal code	: 500 078		



Biological E. Limited

Celebrating Life Every Day

Name of the company : **Biological E. Limited**

Head of Institution : **Ms.Mahima Datla**, Managing Director

Established : **1953**

Location : **India**

Overview of the company

Biological E Ltd (BE) is established in the year 1953 in Hyderabad, India. Over the years, we have built up a very significant share in the world of vaccine market, especially in the paediatric range. Our company is a major supplier to the National Immunization Programme (EPI programme) of the Government of India, UNICEF and Pan American Health Organisation. BE envisages becoming a major world player in vaccine business by expanding the product range, market access, manufacturing facilities and infrastructure through investments, increasing manufacturing and development capabilities and marketing agreements.



BE achieved WHO Prequalification status for various vaccines viz. Tetanus, Pentavalent (DTP-HepB-Hib), Japanese Encephalitis, DTP and Td. BE is the first company to get WHO prequalification by WHO for Japanese Encephalitis vaccine.

As part of continuous efforts to develop new products for human use, BE is currently engaged in development and commercialization of several recombinant, conjugate, bacterial & viral vaccines. BE has productive partnerships with several well respected and renowned Institutions and Public Health Services across the world for joint development of new products to fulfill the unmet needs of India and other regions countries.

Current Product Pipeline

Product Name	Description	Type	Presentation
ComBE Five	Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus type B conjugate vaccine (DTPw-Hep B - Hib) – Liquid Pentavalent	Vial (Liquid)	0.5 / 1.0 / 2.5 / 5.0 ml
ComBE Five	Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus type B conjugate vaccine (DTPw-Hep B + Hib) – Lyophilised Pentavalent	Vial (Liquid + Lyophilised)	0.5 / 1.0 / 2.5 / 5.0 ml
BETT	Tetanus Toxoid (adsorbed) (TT)	Vial & Ampoule	0.5 / 5.0 / 10.0 ml
TRIPVAC	Diphtheria, Tetanus and Pertussis vaccine (adsorbed) (DTPw)	Vial	0.5 / 5.0 ml
JEEV	Japanese Encephalitis Vaccine, Inactivated (Strain SA14-14-2 propagated on Vero cell line)	Vial	0.5ml
BE Td	Diphtheria and Tetanus vaccine (Td) (for adolescents & adults)	Vial	0.5 / 5.0 ml
BIVAC	Diphtheria & Tetanus Toxoid (DT)	Vial	0.5 / 5.0 ml
BEVAC	Hepatitis B vaccine (recombinant)	Vial	0.5 / 1.0 / 2.5 / 5.0 ml
TRIPVAC HB	Diphtheria, Tetanus, w-Pertussis, Hepatitis B (recombinant) (DTPw+HepB)	Vial	0.5 / 1.0 / 2.5 / 5.0 ml
HIBE	Haemophilus type b conjugate vaccine lyophilized) (Hib)	Vial (combipack)	0.5 / 1.0 / 2.5 / 5.0 ml

• Products in bold are pre-qualified

Future Product Pipe Line

- MR – Measles & Rubella
- Hexavalent - DTP-HepB-IPV-Hib
- IPV – Inactivated Polio Vaccine
- PCV - Pneumococcal Conjugate Vaccine
- TCV - Typhoid Conjugate Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Vaccines – Bulk & Finished
- Long term partnership

Contact Details

Name of contact person

: Ms. Kala Naidu, VP – Intl. Marketing
Ms. Divya Bijlwan, VP - SBD

Address

: Road No.35, Jubilee Hills

City

: Hyderabad

State

: Telangana

Location

: India

Postal code

: 500 033

Phone

: +91 40-71216250 / 71216000

Mobile

: +91 9849557083

Fax

: +91 4071216019

email

: Kala.g@biologicale.co.in
divya.bijlwan@biologicale.co.in

Website

: www.biologicale.com





Name of the company : **Bio Farma**
 Head of Institution : **Iskandar**, President Director
 Established : **August 6, 1890**
 Location : **Indonesia**

Overview of the company

Bio Farma is a state-owned vaccine and antisera manufacturer in Indonesia and it plays a vital role in supporting the National Immunization Program. All of vaccines needed by Government are supplied by Bio Farma. The company has an extensive and strong major goal to responsibly endure its high quality vaccine production whilst holding the awareness to persistently develop the green industry by covering all the aspects of the green industry's activities.

Bio Farma was established in 1890 and throughout its extended history, the company has gone a long way from its beginning and has proven its strength to the world. This reputation has always been upheld properly and could be reflected from its magnificent qualification and ability to acquire WHO prequalification for its vaccines.



Bio Farma's products are exported to many countries through the direct distribution or UN agencies. Bio Farma actively involve in various international organizations such as WHO, International Vaccine Institute, DCVMN, GAVI and Self Reliance in Vaccine Production-in OIC.

In order to stimulate more breakthroughs ahead, the company pledge to conduct new products research, both independently or collaborate with research institutions. The partnership could lead to new vaccine development or new technology platform.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
TT	Tetanus Toxoid Vaccine	Vial Uniject	5.0 ml/10.0 ml 0.5 ml
Bio-TT	Tetanus Toxoid Vaccine	Ampoule	0.5 ml
DT	Diphtheria and Tetanus Vaccine	Vial	5.0 ml
Td	Tetanus and Diphtheria Vaccine (for adult)	Vial	5.0 ml
DTP	Diphtheria, Tetanus and whole -cell Pertussis Vaccine	Vial	5.0 ml
DTP-HB	Tetavalent Combination Vaccine	Vial	2.5 ml/5.0 ml
HB	Hepatitis B Vaccine	Uniject	0.5 ml / 1.0 ml (for adult)
mOPV, bOPV	Monovalent, bivalent Polio Vaccine	Vial	2.0 ml
tOPV	Trivalent Oral Polio Vaccine	Vial	1.0 ml/2.0 ml
Measles	Measles Vaccine	Vial	10 doses/20 doses
BCG	Tuberculosis Vaccine	Ampoule	20 doses
Flubio	Seasonal flu Vaccine	Vial	0.5 ml/2.5 ml
DTP-HB-Hib (Pentabio)	Diphtheria, Tetanus, Whole-cell Pertussis, Hep-B and Haemophilus Influenzae type b	Vial	0.5 ml/2.5 ml/5.0 ml

Future Product Pipe Line

- Sabin-IPV (sIPV)
- Rotavirus Vaccine
- Flu Vaccine (Pandemic)
- Measles Rubella Vaccine
- Typhoid Conjugate Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Sabin-IPV (sIPV)					
Rotavirus Vaccine					
Flu Vaccine (Pandemic)					
Measles Rubella Vaccine					
Typhoid Conjugate Vaccine					

Areas of Interest for Collaboration

- Capacity Building
- QMS Training
- Research
- Product Development & Process Innovation
- Marketing & Distribution

Contact Details

Name of contact person : Iskandar

Address : Jl. Pasteur No. 28

City : Bandung

State : West Java

Location : Indonesia

Postal code : 40161


Phone : +62 22 203 3755

Mobile :

Fax : +62 22 204 1306

email : mail@biofarma.co.id

Website : www.biofarma.co.id



Name of the company : **Bio-Manguinhos-Immunobiological Technology Institute**
The Oswaldo Cruz Foundation - Ministry of Health

Head of Institution : **Artur Roberto Couto**

Established : **Avenida Brasil, 4365 – Pavilhão Rocha Lima -**
Manguinhos, Rio de Janeiro - RJ – CEP: 21040-360

Location : **Brazil**

Overview of the company

The Immunobiological Technology Institute - Bio-Manguinhos is a federal laboratory for R&D and production of immunobiologicals in Brazil, created in 1976.



Bio-Manguinhos is a technical-scientific unit of the Oswaldo Cruz Foundation (Fiocruz), which is directly linked to the Brazilian Ministry of Health.

This unit plays a strategic role in its national public health scenario, supplying a range of products - among vaccines, biopharmaceuticals, IVD reagents and services. Thereby, Bio-Manguinhos contributes to the enhancement of the Brazilian Unified Health System (SUS).

Moreover, the Institute has two vaccines prequalified by WHO: Yellow fever and polysaccharide meningitis AC, the first one having already been supplied to more than 70 countries around the world, mainly through the United Nations Agencies.

Bio-Manguinhos has a wide experience with national and global partnerships for co-development and technological transfer processes, and is open to new partnerships with a view to the provision of new biotech products to the population.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Vaccines			
DTP + Hib	<i>Diphtheria, Tetanus, Pertussis and Haemophilus influenza type b</i>	5 doses/vial	2.5 ml
Hib	<i>Haemophilus influenza type b</i>	1 and 5 doses/vial	0,5 and 2,5 ml
MMR	<i>Measles, Mumps and Rubella</i>	10 doses/vial	5,0 ml
MMRV	<i>Measles, Mumps, Rubella and Varicella</i>	1 dose/vial	0,5 ml
OPV	<i>Oral Poliomyelitis</i>	25 doses/tube	2,5 ml
IPV	<i>Inactivated Poliomyelitis</i>	10 doses/vial	5,0 ml
Rotavirus	<i>Rotavirus vaccine</i>	1 dose/vial	2,0 ml
10 – valent Pneumococcal	<i>10 – valent Pneumococcal vaccine</i>	1 dose/vial	0,5 ml
Polysaccharide Meningitis AC	<i>Polysaccharide Meningitis AC vaccine</i>	10 doses/vial	1,5 ml
Yellow Fever	<i>Yellow Fever vaccine</i>	5, 10 and 50 doses/vial	0,5, 1,0 and 25 ml
IVD Reagents			
NAT HIV/HCV	<i>Molecular Biology - NAT HIV/HCV</i>	20 tests/kit	–
Imunoblot DPP® HIV -1/2	<i>Rapid Test - Imunoblot DPP® HIV -1/2</i>	20 tests/kit	–
DPP® HIV – 1/2	<i>Rapid Test – DPP® HIV – 1/2</i>	10 and 20 tests/kit	–
DPP® Syphilis	<i>Rapid Test – DPP® Syphilis</i>	20 tests/kit	–
DPP® Canine Leishmaniasis	<i>Rapid Test – DPP® Canine Leishmaniasis</i>	20 tests/kit	–
DPP® Leptospirosis	<i>Rapid Test – DPP® Leptospirosis</i>	20 tests/kit	–
Chagas Disease IFA	<i>Immunofluorescence – Chagas Disease</i>	600 tests/kit	–
Canine Leishmaniasis ELISA	<i>ELISA - Canine Leishmaniasis</i>	384 tests/kit	–
Human Leishmaniasis IFA	<i>Immunofluorescence – Human Leishmaniasis</i>	600 tests/kit	–
Helm Test	<i>Kato Katz – Helm Test</i>	100 tests/kit	–
Biopharmaceuticals			
Interferon alpha 2b	<i>Interferon alpha 2b recombinant</i>	3, 5 and 10 MUI/vial	1,0 ml
Erythropoietin	<i>Erythropoietin recombinant</i>	2.000 and 4.000 UI/ vial	1,0 ml
Alphataliglucerase		200 UI/vial	5,0 ml

Future Product Pipe Line

- Conjugate Meningitis C vaccine
- DTP/HB/Hib vaccine
- DTP/HB/Hib/MenC/IPV vaccine
- Dengue tetravalent vaccine (inactivated)
- Yellow fever vaccine improvement (attenuated)
- Yellow fever vaccine (inactivated)
- Yellow fever vaccine (plant-based vaccine)
- Leptospirosis vaccine (recombinant)
- Measles and Rubella vaccine
- Polysaccharide meningitis B vaccine
- Peginterferon Alpha 2b
- Humanized monoclonal antibody Anti-MRSA
- Humanized monoclonal antibody Anti-CD20
- Flex NAT Kit
- NAT Kit -HIV/HCV/HBV/malaria
- DPP® Syphilis treponemal and non-treponemal
- CD3CD4CD8CD45 kit
- Liquid Microarray

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Bacterial vaccines	2		1	2	-
Viral vaccines	5				-
Biopharmaceuticals	2			1	-
IVD reagents	4			1	-

Areas of Interest for Collaboration

- Prokaryotic expression
- Eukaryotic expression
- Conjugation
- Plant based

Contact Details

Name of contact person	: Mrs. Denise Maria Lobo Crivelli	Phone	: +55 21 3882-9329
Address	: Avenida Brasil, 4365 - Manguinhos	Mobile	: +55 21 99395-0839
City	: Rio de Janeiro	Fax	: +55 21 3882-7176
State	: Rio de Janeiro	email	: dlobo@bio.fiocruz.br
Location	: Brazil	Website	: www.bio.fiocruz.br
Postal code	: 21040-360		





Name of the company : **BioNet-Asia Co., Ltd.**

Head of Institution : **Mr. Vitoon Vonghangool**, President
Dr. Pham Hong Thai, Chief Executive Officer

Established : **2001**

Location : **Thailand**

Overview of the company

BioNet-Asia is an independent vaccine company with a focus on technological innovation and market access.

BioNet has built several strategic alliances fostering vaccine self-reliance leading to the production and supply of billions of doses of vaccines worldwide. In its vaccine manufacturing plant in Thailand, BioNet is developing a broad pipeline of vaccines in R&D and clinical stages, such as recombinant Pertussis, CRM197 protein carrier, Dengue and Hepatitis B vaccines. The company has successfully transferred the technology in Asia to produce Hib meningitis vaccine which is now commercialized and pre-qualified as a pentavalent vaccine. BioNet has also filed a patent application for a new

Recombinant Acellular Pertussis Vaccine that has been shown safe and highly immunogenic in a Phase I/II study. BioNet has several collaborations with first-class biopharmaceutical companies, vaccine manufacturers and academic organizations around the globe.

With a global market reach and network expertise, BioNet has been supporting vaccine manufacturers in their rapid expansion into international and emerging markets, finding and capitalizing on new growth opportunities.

Through its unique collaboration with many manufacturers, BioNet can propose a broad portfolio of vaccines in several countries.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hib*	<i>Haemophilus influenzae</i> type b vaccine in combined pediatric formulation		
TRCS Rabies*	Rabies vaccine	Vial	0.5mL

*In partnership

Future Product Pipe Line

- Recombinant acellular pertussis (aP) vaccine
- Adult combinations (TdaP based vaccines)
- Hepatitis B vaccine (HBV)
- Pediatric combinations
- Dengue vaccine
- Human papillomavirus vaccine (HPV)
- Japanese Encephalitis vaccine
- Chikungunya vaccine
- Protein carriers

Product Name	Product development R&D phase	Pre Clinical	Phase 1	Clinical Phase 2	Phase 3	Expected launch date Quarter / Year
Recombinant acellular Pertussis vaccine						
Adult combination vaccine						
<i>Haemophilus influenzae</i> type b vaccine						Already transferred the technology and launched the product in Asian country

Areas of Interest for Collaboration

- Marketing and Distribution of vaccines
- Vaccine joint development and R&D collaborations
- Technology transfer forHib, HBV, HPV, Rabies
- In- and out-licensing opportunities

Contact Details

Name of contact person	: Dr. Pham Hong Thai	Phone	: +66-3524 6924
Address	: Hi-Tech Industrial Estate, 81 Moo 1, Baan Lane, Bang Pa-In	Mobile	:
City	: Ayutthaya	Fax	: +66-35246925
State	: Ayutthaya	email	: info@bionet-asia.com
Location	: Thailand	Website	: www.bionet-asia.com
Postal code	: 13160		



Name of the company : **Bravo Vax Co., Ltd.**

Head of Institution : **Dr. Ke WU**

Established : **2012**

Location : **P.R. China**

Overview of the company

Established in 2012, BravoVax is located at East Lake Hi-tech Development Zone, Wuhan, China. Relying on the experienced management team and international resources of parent company BravoBio, and with the strong support of Humanwell Healthcare Group, one of the top 20 Chinese pharmaceuticals, the company has kept the momentum in its development, and maintains fast growth. The company has signed strategic cooperation agreements with world famous high-end equipment manufacturers and established Joint Standard Laboratory with them. In October 2014, the company was sublicensed the world-wide (Excl. US, JP & EU) rights for the rotavirus vaccine from USA hence set a solid foundation to the

development of the company and will conduct a series of high-end vaccine industrialization development in compliance with WHO cGMP.

96% staffs of the company hold college and above degrees, and more than 30% of them have master and above degrees as well as senior professional titles. The company boasts its strong R&D team with profound performances and experiences.

Regard human vaccines as its core business, BravoVax motivates biopharmaceutical business development and resources integration; abides by the strategy to be a resource-friendly and environment-friendly enterprise; aims to be one of the best employers and the most respected enterprises.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Rotavirus vaccine	Oral, tetra-valent, attenuated; IND stage	Freeze-dried	2 ml

Future Product Pipe Line

N/A

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Co-dev of new type of vaccines
- Tech-in/license-in of vaccine-related technology, patents, etc.
- Export of biologicals/vaccine bulk from Chinese manufacturers

Contact Details

Name of contact person

: Dr. Song QIU

Address

: BravoVax Building
BioPark, 858 Gaoxin Avenue,
Donghu Dev. Zone

City

: Wuhan

State

: Hubei Province

Location

: P.R. China

Postal code

: 430075

Phone

: +86 27 8798 8585

Mobile

:

Fax

: +86 27 8798 8595

email

: song.qiu@bravovax.com

Website

: www.bravovax.com





Name of the company : **Cadila Pharmaceuticals Limited**
 Head of Institution : **Dr. Rajiv I. Modi, Chairman & Managing Director**
 Established : **28-02-1991**
 Location : **India**

Overview of the company

Cadila Pharmaceuticals is one of the largest privately held pharmaceutical companies in India. Over the last few decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 90 countries around the world. It is a research-driven integrated healthcare solutions provider with a pharmaceutical product basket of 450 plus in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art Research and Development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists.

The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drugs applications (INDs) cleared by USFDA.

The company has manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia.



Cadila Pharmaceuticals has recently emerged on the World map with the development of world's first introductions like 'Polycap'- a novel drug combination for prevention of Cardiovascular Heart Disease; and 'Risorine', a boosted Rifampicin dosage for TB treatment. Cadila Pharmaceuticals also has a strong footprint in micropropagation and bioformulation through its Agro division.

Cadila Pharmaceuticals Ltd. has also formed a joint venture with Novavax, Inc. USA. The JV-CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Pandemic Influenza	H1N1 vaccine produced from VLP technology	Vial/PFS	0.5 ml/2ml vial
Seasonal Influenza Vaccine	Trivalent Influenza vaccine produced from VLP technology	Vial/PFS	0.5ml/2ml vial
Rabies vaccine	Recombinant G-Protein produced by VLP technology	Vial/PFS	0.5ml/2ml vial

Future Product Pipe Line

- Hepatitis E
- Rabies One Dose vaccine
- Qadivalent flu
- Malaria Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Pandemic Influenza					Q4 / 2015
Seasonal Influenza					Q1 / 2016
Rabies Vaccine					Q3 / 2017

Areas of Interest for Collaboration

- Vaccine - recombinant
- Vaccine - cell culture based
- Conjugate vaccine
- Adjuvant (Biological and small molecules)
- Recombinant proteins and Monoclonal antibody for therapeutic use
- In licensing /out licensing

Contact Details

Name of contact person : **Mr. Raj Mehta**
President - Biotech

Address : **Cadila Pharmaceuticals Limited**
1389, Trasad road, Dholka

City : **Ahmedabad**

State : **Gujarat**

Location : **India**

Postal code : **387810**

Phone : **+91- 2714 221 481/83/84**

Mobile : **+91- 9099090270**

Fax : **+91- 2714 220 315**

email : **raj.mehta@cplbio.com**

Website : **www.cadilapharma.com**



Name of the company : **Center for Research and production of Vaccine and Biological (POLYVAC)**

Head of Institution : **Dr. Nguyen Dang Hien, Director**

Established : **24 January 1994**

Location : **Hanoi, Vietnam**

Overview of the company

Center for Research and Production of Vaccines and Biologicals (POLYVAC) was established in 1994 by the Ministry of Health of Vietnam with the task of carrying out experimental research, application of new technologies for production of Vaccine and biological products

From the end of 1962, the Division of Sabin's Oral Polio Vaccine Production of the NIHE was able to produce 2 million doses of oral polio vaccine for children of North Vietnam. With the great efforts of all professionals and staff, with unity and self sufficiency spirit in



order to fulfill the assigned tasks and duties, the quantity of vaccine produced by the Center has increased every year up to 40 million doses, meeting the national vaccination demand for eventual recognition in 2000 by WHO that Vietnam was polio free.

Besides the production of OPV, Center also conducts research and produces other vaccines such as: IPV, Rotavirus vaccines and Measles vaccines meets GMP/WHO with technology transferred by Japan. At present, Measles vaccine has been licensed. Since 2010, Vietnam will stop importing measles vaccine, while being active in preventing and controlling measles as recommended by WHO. The Rotavirus vaccine is has been licensed also from 2012.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Oral polio vaccine	Tetravalent, live, attenuated oral vaccine	Vial	2ml/20 doses/vial
Measles Vaccine	Freeze-dried, live attenuated vaccine. AIK-C Strain	Vial	5ml/10 doses/vial
Rotavirus vaccine	Live attenuated oral vaccine. Human strain G1P[8]	Vial	2ml/1 dose/vial

Future Product Pipe Line

- Rubella
- Measles-Rubella combine vaccine
- Inactivated Polio vaccine
- bOPV

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
bOPV					Q4 /2015
MR					Q4 /2016
IPV					Q3 /2016

Areas of Interest for Collaboration

Contact Details

Name of contact person : **Dr. Nguyen Dang Hien, Director**

Address : **135 Lo Duc Street**

Phone : **+84 4 3 8211782**

City : **Hanoi**

Mobile : **+84 913236890**

State :

Fax : **+84 4 38213203**

Location : **Vietnam**

email : **danghien@fpt.vn**

Postal code: **10000**

Website: **polyvac.com.vn**



Name of the company : **Changchun BCHT Biotechnology Co.**

Head of Institution : **Dr. Kong Wei**

Established : **March, 2004**

Location : **P.R. China**

Overview of the company

Changchun BCHT Biotechnology Co., a biopharmaceutical enterprise specializing in research, development, production and marketing of vaccines, biologics and peptide & chemical drugs, was established in March 2004.

BCHT has well-established innovative platform and extensive cooperative network. Each year the company invests considerable amount of money from the sales into R&D for innovative and qualified healthcare products, and the sum of R&D investment exceeds over 100 million RMB for the last few years. BCHT owns among the most advanced R&D laboratories and pilot plants for vaccines, gene engineering biologics and peptide drugs in China. The facilities, in area over 5000m² and with



more than 500 sets of instruments and equipments

As a fast-growing enterprise, BCHT not only focuses on the domestic market but also aims at exploring international market and business opportunity. The company has established successively trade cooperation with partners in areas such as Southeast Asia, the Middle East, Africa and South America etc. The registration for BCHT products has been undertaken in many countries. The company has taken part in government purchase in various countries and won the bidding successfully. BCHT has started to export its products to international market since 2009.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Varicella Vaccine, Live	gelatin-free, validity for 36 months, lyophilized, Oka strain	Vial	0.5ml/vial
Rabies Vaccine (Vero Cell) for Human Use	Produced with microcarrier bioreactor, with high potency not less than 2.5IU	Vial	1.0ml/vial

Future Product Pipe Line

- Acellular DTP Vaccine
- Live Attenuated InfluenzaVaccine
- HPV Vaccine
- AIDS Vaccine
- RSV Vaccine
- VZV Vaccine
- Cancer Vaccine
- EV71 Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Acellular DTP Vaccine	—				2016
Live Attenuated InfluenzaVaccine	—				2016
HPV Vaccine	—				2018
AIDS Vaccine			—		
RSV Vaccine	—				
VZV Vaccine	—				
Cancer Vaccine	—				
EV71 Vaccine	—				

Areas of Interest for Collaboration

- Vaccines
- Peptide and chemical drugs
- Biologics
- Export

Contact Details

Name of contact person	: Wu Jinchang	Phone	: +86- 431- 85879036
Address	: 1260 Huoju Road, Changchun National High-tech Industry Development Area, Changchun Jilin 130012 P.R. China	Mobile	: 15044068371
City	: Changchun	Fax	: +86- 431- 8519 5516
State	: Jilin Province	email	: wujinchang@bchtpharm.com
Location	: P.R. China	Website	: www.bchtpharm.com
Postal code	: 130012		





中国生物技术集团
China National Biotec Group

Name of the company : **China National Biotec Group (CNBG)**

Head of Institution : **Dr. Yang Xiaoming**, President

Established : **1989**

Location : **P.R. China**

Overview of the company

CNBG is a state-owned company and one of the subsidiaries of China National Pharmaceutical Group Company (Sinopharm). It's the largest vaccine and blood products manufacturer and supplier in China and has been dedicated in the field of healthcare for nearly a century. CNBG consists of six institutes of biological products which are located in Beijing, Changchun, Chengdu, Lanzhou, Shanghai, Wuhan respectively. CNBG is also the major shareholder of Beijing Tiantan Biological Products Co., Ltd. and Beijing Vigoo Biological Co., Ltd.



CNBG has nearly 10000 employees, among which more than 4000 are scientists and technicians. CNBG owns dozens of achievements with independent intellectual properties rights and are currently operating more than a hundred SFDA cGMP certified manufacturing lines enabling to manufacture over 200 types of biological products for disease prevention, therapeutic and diagnostic use, also including all the vaccines for Chinese EPI program.

CNBG has successfully integrated a flow of R&D, manufacturing, marketing and post-marketing activities for biological products and has become one of the few companies in the world that could offer the widest range of vaccines with large quantities.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
	Hepatitis B vaccine (yeast)	Ampoule	5,10,20 µg
	BCG vaccine for intradermal injection	Ampoule	0.25mg/5doses
	tOPV(dragee candy)	Pill	1g
Shanliantai	Diphtheria Tetanus and Acellular Pertussis combines(DTaP), Adsorbed	Ampoule/vial	0.5ml
	Measles, Mumps and Rubella combined vaccine, Live(M/R/MR/MM/MMR)	vial	0.5ml
CD.JEV	Japanese Encephalitis Vaccine Live	vial	0.5ml
Mengllingkang	Group A+C Meningococcal Polysaccharide vaccine	Ampoule	100µg/dose,400µg/4doses
	Group A Meningococcal Polysaccharide vaccine	Ampoule	150µg/5doses, 300µg/10doses
Havac	Live attenuated Hepatitis A vaccine	vial	1ml
	Split Influenza virus vaccine	Injector/vial	0.25ml, 0.5ml
Huiyikang	23 Valent Pneumococcal Polysaccharide vaccine	vial	0.5ml
Loutewei	Live Rotavirus Vaccine (oral)	vial	3ml
Keerbei	Haemophilus Influenza type b conjugate vaccine	vial	0.5ml
Shengdoushi	Freeze-dried Live attenuated Varicella vaccine	vial	0.5ml
Wushengxinning	Rabies Vaccine for human use(vero cell)	vial	0.5ml X 5vial /dose
	Yellow Fever Vaccine, Live	Ampoule	0.3ml/6doses
	Typhoid Vi Polysaccharide vaccine	Ampoule	1ml/2doses
Sentaibao	Tick- Borne Encephalitis Purified Vaccine	Ampoule	1ml
	Human Albumin	vial	2g,5g,10g,12.5g
	Human Immunoglobulin (pH4) Intravenous Injection	vial	1.25g, 2.5g,5g
	Human Hepatitis B/Tetanus/ Rabies Immunoglobulin	vial	100IU,200IU/ 250IU/ 200IU per vial
Hengli	Botulinum Toxin A for injection	vial	5,10,20 µg
	Murine Monoclonal Antibody Anti-Human CD3 antigen of T Lymphocyte	vial	5ml

Future Product Pipe Line

Product Name	Pre Clinical	IND Filed	Phase 1	Clinical Phase 2	Phase 3	Expected launch date Quarter / Year
Beijing Strain Varicella Live Attenuated Vaccine						
Ev71 Vaccine						
Trivalent Reassortant Rotavirus Vaccine						
Typhoid Vi Conjugate Vaccine						
Group A+C Meningococcal Conjugate Vaccine						
ACYW135 Meningococcal Polysaccharide Conjugate						
Hexavalence Rotavirus Vaccine						
13-valent Pneumococcal Conjugate Vaccine						
Recombinant Hexavalent Human Papillomavirus						
slPV						
Lyophilized Herpes Zoster Inactivated Vaccine						
Measles, Mumps, Rubella and Varicella Combined Vaccine Live (MMRV)						
DTaP+Hib						

Areas of Interest for Collaboration

- Large-scale Production Technology
- Combined Vaccine
- Cell line
- New Antigen
- Adjuvant

Contact Details

Name of contact person : **Ms.TANG Ying ; Ms.QU Liang**

Address : **16th Floor, Fortune Tower B,
No.A4 Huixin-East Street, Chaoyang District**

City : **Beijing**

State : **Beijing**

Location : **P.R. China**

Postal code: **100029**

Phone : **+86 10 8466 3879
+86 10 8466 3787**

Fax : **+86 10 8466 3322**

Mobile : **+86 135 0108 1655
+86 136 2110 6475**

email : **tangying@cnbg.com.cn
quliang@cnbg.com.cn**

Website: **www.cnbg.com.cn**



Name of the company : **EuBiologics, Co. Ltd.**

Head of Institution : **Dr. Yeong-Ok Baek, CEO**

Established : **March 10, 2010**

Location : **Republic of Korea**

Overview of the company

EuBiologics Co., Ltd. is a privately-held Korean biopharmaceutical company providing contract research and manufacturing services to domestic and international clients, in addition to building a portfolio of vaccines designed to improve global public health. The company was established in March 2010 with the objective of becoming a preferred strategic partner providing solutions for the development and manufacturing of biopharmaceutical products. EuBiologics's facilities are designed to manufacture a variety of mammalian cell and microbe-derived, protein-based therapeutics and antibodies. It provides customized services for various stages of product development, including cell line development, "Good Manufacturing Practice" (GMP) production, validation and regulatory support.



The company has also licensed the manufacturing technology necessary to produce an oral cholera vaccine from the International Vaccine Institute. In parallel with the development of its oral cholera vaccine product ("Euvichol"), EuBiologics is pursuing a number of other vaccines against diseases such as typhoid fever, HPV and norovirus.

The company's administrative headquarters is in Seoul and its manufacturing facilities are located in a biotechnology cluster in Chuncheon, Korea. For additional information about the company, please visit <http://www.eubiologics.com/ENG/>.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Euvichol®	Oral Cholera Vaccine	Vial	1.5 ml

Future Product Pipe Line

- Typhoid Conjugate Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Typhoid conjugate vaccine					

Areas of Interest for Collaboration

- Development of bacterial conjugate vaccines
- Development of combo vaccines
- New adjuvant development and application to bacterial vaccines

Contact Details

Name of contact person	: Rachel Park	Phone	: +82 02 572 6675
Address	: 6F Bomnal-A-Chim B/D, Mabang-ro 8, Seocho-gu	Mobile	: +82 10 4262 8187
City	: Seoul	Fax	: +82 02 574 6678
State	:	email	: rachel.park@eubiologics.com
Location	: Republic of Korea	Website	: www.eubiologics.com
Postal code	: 137-894		



Name of the company : **Finlay Institute**

Head of Institution : **Dr. Concepción Campa Huergo**, President / General Director

Established : **27th Ave No. 19805, La Coronela La Lisa, Habana City**

Location : **Cuba**

Overview of the company

The FINLAY INSTITUTE, founded in 1991, is a scientific organization, dedicated to research, development, production and commercialization of human vaccines, internationally recognized in this field. This institution is a world leader in the field of meningococcal vaccine and other classic vaccines included in the Extended Immunization Program (EIP). VA-MENGOC-BC®, created and produced by the Finlay Institute was the first effective vaccine against serogroup B meningococcus.



The almost 1000 members of Finlay's staff constitute the largest capital of Finlay Institute and they have been recognized for their experience in the field of vaccines, more than 60% of them have high technical and professional qualification in the field of vaccine research, development, production and quality control. Many of them have more than 20 years of experience in these specialties, which guarantees the preparation and continuity of the projects with the inclusion of new talents graduated from the universities.

The facilities engaged in the production of vaccines and active pharmaceutical ingredients were designed, built, equipped and they are operated according to cGMP. Some products manufactured in these facilities have been prequalified by WHO.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
VA-MENGOC-BC®	Meningococcal BC vaccine	Vial	0.5/2.5/5.0 ml
vax-MEN-AC®	AC Meningococcal polysaccharide vaccine	Vial	5.0 ml
vax-MEN- ACW ₁₃₅ ®	Meningococcal ACW ₁₃₅ vaccine	Vial	5.0 ml
vax-SPIRAL®	Trivalent leptospirosis vaccine	Vial	0.5/5.0ml
vax-TyVi®	Vi polysaccharide typhoid vaccine	Vial	0.5/5.0/10.0 ml
vax-TET®	Tetanus vaccine	Vial	0.5/5.0/10.0 ml
VA-DIFTET®	Diphtheria-Tetanus vaccine for children	Vial	0.5/5.0/10.0 ml
dT-vax®	Diphtheria-Tetanus vaccine for adults	Vial	0.5/5.0/10.0 ml
DTP-vax®	Diphtheria- Tetanus-wPertussis vaccine	Vial	0.5/5.0/10.0 ml

Future Product Pipe Line

- Cholera vaccine (attenuated)
- Plain ACYW₁₃₅ meningococcal vaccine (porcine components free)
- AW₁₃₅ OMV vaccine
- Plain polysaccharide Vi Vaccine (porcine components free)
- Plain ACYW₁₃₅ X meningococcal vaccine
- AW₁₃₅ X OMV vaccine
- Conjugated Vi polysaccharide vaccines
- Conjugated Meningococcal ACYW₁₃₅ X vaccine
- Onco BCG

Product Name	Pre	Clinical	Expected launch date		
	Phase 1	Phase 2	Phase 3	Quarter	Year
Cholera vaccine (attenuated)					
Plain ACYW ₁₃₅ meningococcal vaccine (porcine components free)					
AW ₁₃₅ OMV vaccine					
Plain polysaccharide Vi Vaccine (porcine components free)					
Plain ACYW ₁₃₅ X meningococcal vaccine					
AW ₁₃₅ X OMV vaccine					
Conjugated Vi polysaccharide vaccines					
Conjugated Meningococcal ACYW ₁₃₅ X vaccine					
Onco BCG					

Areas of Interest for Collaboration

- Cooperated manufacturing
- Vaccine technologycal transfer
- Bacterial vaccines development based on outer membrane vesicles and based on capsule polysaccharides
- Application of novel adjuvants based on serogroup B Neisseria meningitidis outer membrane vesicles and proteoliposome-derived cochleate structure for vaccine development

Contact Details

Name of contact person : **Dr. Concepción Campa Huergo**

Address : **Ave 27 No. 19805, La Coronela, La Lisa,**

Phone : **+ 53 7 208 6086**
+ 53 7 208 0976

City : **Havana**

Mobile : **+ 535 285 0016**

State :

Fax : **+ 53 7 208 6075**

Location : **Cuba**

email : **ccampa@finlay.edu.cu**

Postal code: **11600**

Website: **www.finlay.edu.cu**



Name of the company : **Fundação Ataulpho de Paiva**
 Head of Institution : **Germano Gerhardt Filho**
 Established : **1900**
 Location : **Brazil**

Overview of the company

Fundação Ataulpho de Paiva (FAP) is a nonprofit, philanthropic private institution founded in 1900 and was named Brazilian League Against Tuberculosis. FAP has been promoting scientific advances and producing BCG Moreau Rio de Janeiro vaccine strain since 1930. FAP activities are based on production, research and social assistance programs. The Brazilian Ministry of Health has given competence to the Fundação for manufacturing, importing, exporting, stocking, distribution and repackaging of drugs, raw materials and dietary products.



BCG Moreau Rio de Janeiro is one of the four BCG vaccines considered as Reference Reagent by the World Health Organization (WHO). In 2012 the Moreau strain was studied by 16 laboratories from 13 countries certified by WHO.

The high immunogenicity and low side effects of the Brazilian vaccine have been demonstrated. The genome sequence and proteome analysis of the strain were also studied.

In 2006 IMUNO BCG® was launched in Brazil. It was developed from The BCG Moreau Rio de Janeiro strain. It is used for the treatment of superficial bladder cancer.

Currently, FAP has a new factory under construction to increase the production according to Good Manufacturing Practices (GMP). The institution is also researching for advances in the development of tuberculosis drugs.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
BCG	BCG Vaccine	Vial	1mg/10 doses
IMUNO BCG	IMUNO Therapy	Vial	40mg/Intrabladder

Future Product Pipe Line

Product Name	Pre Clinical		Clinical		Expected launch date Quarter / Year
	Phase 1	Phase 2	Phase 3	Phase 3	

Areas of Interest for Collaboration

Contact Details

Name of contact person : **Luiz Roberto Castello-Branco**

Address : **Av. Pedro II, 260/270 – São Cristóvão**

City : **Rio de Janeiro**

State : **Rio de Janeiro**

Location : **Brazil**

Postal code: **20941-070**

Phone : **+55 21 2589-8670**

Mobile : **+55 99457-6164**

Fax : **+55 21 2589-8934**

email : **branco@bcgfap.com.br**

Website: **<http://www.fundacaoataulphodepaiva.com.br>**





Name of the company : **GreenCross Corporation**

Head of Institution : **Il-Sup Huh**

Established : **1967**

Location : **Republic of Korea**

Overview of the company

Green Cross Corporation (GCC) is one of the leading research based biomedical and pharmaceutical companies in Korea. The corporate headquarter and R&D facilities are located in Yongin. GCC has 3 production plants. Since its establishment in 1967, GCC has pioneered in the field of biopharmaceuticals, such as vaccines, plasma-derivatives, diagnostics, recombinant proteins and therapeutic antibodies.

GCC has been well known for the R&D and commercialization of 'Hepavax B', a world's biggest selling hepatitis B vaccine, 'Hantavax', a world's first epidemic hemorrhagic fever vaccine, and 'Suduvax', a world's second chicken pox vaccine. Starting from the nation's first Albumin production in 1971, it currently manufactures more than 12 plasma fractions including immunoglobulin, anti-hemophilic factors, and anti-thrombin factor. Manufacturing over 250 diagnostic reagents in 41 items, GCC is the leader in the nation's diagnostic reagent sector. Recent innovations include 'rhFVIII (GreenGene™)', a recombinant human coagulant factor VIII and a complete flu pipeline including seasonal flu vaccine (GCFLU®), H1N1 vaccine, avian flu vaccine as well as flu therapeutics, Peramivir. GCC is also pursuing opportunities in rare diseases developing therapies for Hunter syndrome (Hunterase™) which is world 2nd, and is designated as orphan drug by MFDS.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
GC FLU	Generic name: Split virion inactivated Influenza Vaccine A sterile suspension containing influenza virus which is propagated in the allantoic fluid of embryonic chicken egg.	pre-filled syringe	0.5ml, 0.25ml
Japanese Encephalitis Vaccine- GCC inj.	Generic name: Inactivated Japanese Encephalitis Vaccine	Vial	0.5ml, 1ml
Varicella Vaccine – GCC inj.	A sterile suspension containing Japanese Encephalitis virus of Nakayama strain inactivated by formalin		
Varicella Vaccine – GCC inj.	Generic name: Live attenuated Varicella Vaccine A freeze-dried, live attenuated varicella-zoster vaccine. When reconstituted, the product is a transparent suspension of colorless or yellowish color	Vial	0.7ml

* More detailed information of GCC' full list of current product pipeline & future product pipeline is available at www.greencross.com.

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Avian Influenza vaccine					
Adult Td vaccine					
Anthrax vaccine					
Cell Culture Influenza vaccine					
Tdap vaccine					
Varicella Zoster vaccine					

Areas of Interest for Collaboration

- Development and marketing partnership for novel vaccine products
- Co-development and commercialization of biologics for rare disease (Hunter syndrome, Hemophilia A)
- In-Licensing partnership for novel oncology or orphan products
- In-Licensing partnership for novel technology

Contact Details

Name of contact person : **Haiyan Nan**

Address : **303 Bojeong-dong, Giheung-gu, Yongin,**

Phone : **+82-31-260-9106**

City : **Yongin**

Mobile : **+82-10-9401-0410**

State : **Gyeonggi-do**

Fax : **+82-31-260-9408**

Location : **Republic of Korea**

email : **hynan@greencross.com**

Postal code: **446-770**

Website: **www.greencross.com**



Name of the company : **Haffkine Bio-Pharmaceutical Corporation Limited**

Head of Institution : _____

Established : **1974**

Location : **India**

Overview of the company

The Haffkine Bio-Pharmaceutical Corporation was incorporated in 1974, aiming to take-up and expand the production of the erstwhile Haffkine Institute and to manufacture standard biological and non-biological products of public health importance. The Company established a subsidiary Company in 1977 viz. Haffkine Ajintha Pharmaceuticals Ltd at Jalgaon, producing tablets, capsules, powders, ointments etc.

Haffkine is engaged in the manufacture and supply of biological and non-biological products especially bacterial and viral vaccines, antisera, toxoids, injectables and pharmaceuticals in the pursuit of its mission of "Service to Mankind in the Health Care Sector".



The Company has contributed significantly towards the universal immunization and the Polio Eradication Programme, launched by the Government of India, ensuring timely supply of Oral Polio Vaccine (OPV) in sufficient quantity.

The Company has WHO-GMP prequalification for its Oral Polio Vaccines (mOPV1, bOPV(1&2) and tOPV) for supply to UNICEF.

Haffkine timely and adequately supplies all its products at affordable prices to all the Public Health Institutions of Government of Maharashtra.

Specific initiatives are underway for meeting the demands for the lifesaving drugs in other States, as well as in other countries. The Company plans to increase vaccine/antibodies production and diversify into the manufacture of newer vaccines of social relevance.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
tOPV	trivalent Oral Polio Vaccine	Vial	2.2 ml (20 doses)
bOPV(1&3)	Bivalent Oral Polio Vaccine	Vial	2.2 ml (20 doses)
mOPV(1)	Monovalent Oral Polio Vaccine	Vial	2.2 ml (20 doses)
ASVS	Anti Snake Venom Serum	Vial	10 ml
AScVS	Anti Scorpion Venom Serum	Vial	10 ml
ARS	Anti Rabies Serum 300 IU/ml	Vial	5 ml
ADS	Anti Diphtheria Serum 10000IU	Vial	5 ml
ATS	Anti Tetanus Serum 1500IU/ml	Ampoule	1 ml

Future Product Pipe Line

- Tissue Culture Anti Rabies Vaccine (TCARV)
- AGGS

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Measles
- Hep B
- HiB
- IPV
- Pneumococcal vaccine

Contact Details

Name of contact person : Mr. Prakash R. Sabde

Address : Acharya Donde Marg, Parel

City : Mumbai

State : Maharashtra

Location : India

Postal code: 400012

Phone :+91-22-24129320-22
(Direct) +91-22-24150628

Mobile : +91-9422783400

Fax : +91-22-24168578

email : md@vaccinehaffkine.com

Website: www.vaccinehaffkine.com





Name of the company : **Incepta Vaccine Ltd**
 Head of Institution : **Abdul Muktadir**, Managing Director
 Established : **2011**
 Location : **Bangladesh**

Overview of the company

Incepta Vaccine Ltd is the first human vaccine manufacturing company in Bangladesh established with the objective to provide vaccine at an affordable cost.



IVL has state-of-the-art facility compliant with WHO GMP requirements with capacity to manufacture 180 million doses per year of any dose size from 0.1 ml to 15 ml.

It has an advanced GMP compliant R&D facility, bulk antigen facility with modern production fermenters, large animal house and well designed spacious several cold rooms (from -20°C to +8°C). to store raw materials and finished products.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Rabix-vc	Rabies vaccine (Human), 2.5 IU/1ml	Vial	1 ml
Vaxitet	Adsorbed Tetanus vaccine, 40 IU/0.5 ml	vial	0.5 ml
Vaxphoid	Typhoid Polysaccharide vaccine, 25 µg/0.5 ml	Vial	0.5 ml
Hepa-B	Hepatitis B surface antigen, 20 µg/1ml, 10 µg/ 0.5ml,	Vial	1 ml & 0.5 ml
Influvax	Inactivated Influenza vaccine	Vial	0.5 ml
Ingovax ACWY	Meningococcal ACWY Polysaccharide vaccine, 50 µg each.	Vial	0.5 ml
Rabix-IG	Rabies Immunoglobulin of Equine origin, 1000 IU/ 5ml	Vial	5 ml
Vaxitet-IG	Tetanus Antitoxin of Equine origin, 3000 IU/1 ml	Vial	1 ml
Antivenom	Snake Venom Antiserum	Vial	10 ml

Future Product Pipe Line

- Measles and Rubella vaccine
- Pneumococcal polysaccharide vaccine
- Human Tetanus Immunoglobulin
- Human normal immunoglobulin

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Cholera					
Meningococcal ACYW135 polysaccharide vaccine					
Typhoid polysaccharide conjugate vaccine					

Areas of Interest for Collaboration

IVL is open for collaboration with other vaccine manufacturers and research organizations.
We intend to take up projects for co-development of vaccines required for the developing nations.

Contact Details

Name of contact person	: Abdul Muktadir	Phone	: +880-2-8891688-703
Address	: 40, Shahid Tajuddin Ahmed Sarani Tejgaon I/A	Mobile	: +88-01711522330
City	: Dhaka	Fax	: +880-2-8891190
State	:	email	: muk@inceptapharma.com
Location	: Bangladesh	Website	: www.imbcams.ac.cn
Postal code	: 1208		





Name of the company : **Indian Immunologicals Limited**

Head of Institution : **Shri K.V.Balasubramaniam**, Managing Director

Established : **1982**

Location : **India**

Overview of the company

National Dairy Development Board set up Indian Immunologicals Limited in 1982. IIL is a major player in the human vaccine market in India, holding the fourth position and focusing on the pediatric and rabies segment with its flagship product "Abhayrab". IIL is also a major supplier of vaccines to India's large Universal Immunization Programme. IIL's concept of "Abhay Clinic", which provides vaccination service by qualified medical practitioners working on franchise basis, is unique.

IIL strongly believes that its mission of "Biotechnology in health care made affordable and accessible" can be actively pursued only with its sound technology base in modern biotechnology.

IIL research efforts are directed at developing frontier technologies in biologicals, diagnostics and vaccines. IIL has research collaborations with several reputed national and international institutes.

IIL exports its products to more than thirty five countries across the world with customer focus in Middle East, Asia Pacific region, Africa and CIS countries.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Abhayrab	Vero cell culture Rabies vaccine	Freeze dried vial with diluent ampoule	0.5 and 1ml
Elovac B	Recombinant Hepatitis B vaccine	Vial	0.5, 2.5 and 5 ml
Abhay TAG	Diphtheria, Pertussis and Tetanus vaccine	Vial	0.5, 1, 5 and 10 ml
Abhay DAG	Diphtheria and Tetanus vaccine	Vial	0.5 and 5 ml
Abhay TOX	Tetanus vaccine	Vial	0.5 and 5 ml
Abhay RIG	Equine Rabies immunoglobulins	Vial	0.5 and 5 ml

Future Product Pipe Line

- Tetravalent vaccine (DPT+H)
- Pentavalent vaccine (DPTH+HiB)
- Japanese Encephalitis vaccine
- Chikungunya vaccine
- Human Papilloma virus vaccine
- Hepatitis A vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- IPV vaccine technology
- Varicella vaccine technology
- Pneumococcal vaccine
- Dengue Vaccine
- Typhoid conjugate vaccine
- Rotavirus vaccine

Contact Details

Name of contact person : **Dr. Anand Kumar, Ph.D**, Deputy Managing Director

Address : **Indian Immunologicals Limited,
Rakshapuram, Gachibowli Post**

Phone : **+91 40 2300 0542**

City : **Hyderabad**

Mobile : **+91 96663 39987**

State : **Andhra Pradesh**

Fax : **91-40-23000213**

Location : **India**

email : **anandkumar@indimmune.com**

Postal code: **500 032**

Website: **www.indimmune.com**



Name of the company : **Institute of Vaccines & Medical Biologicals (IVAC)**

Head of Institution : **Dr. Le Van Be**

Established : **October, 2012**

Location : **Vietnam**

Overview of the company

On November 23rd , 1978, the Ministry of Health made the decision to establish Institute of vaccines and biological substances (changed to INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS – IVAC from 2006) with functions and responsibilities as following:

- To plan and carry out the production of vaccines and serum, mainly to supply the Expanded Program on Immunization in Vietnam (EPI), and the others for prevention and treatment of diseases.
- To do research and apply technological advances in production and development of vaccines, serum and other biological substances.
- To co-operate with organizations in the country and abroad in the research and production of vaccines, serum and other biological substances, in order to expand production and raise their quality.



- To provide training to our staffs, to manage the allocated budget and state-owned property. Step by step to control the products and approach self - sustainability about outlay.

IVAC consists of 2 establishments:

- Nha Trang establishment, with an area of 3,946m².
 - o Main establishment of IVAC
 - o Produce vaccines and medical biologicals
 - o Conduct scientific and applied research
- Suối Dầu breeding farm - with an area of 126 hectare, 22 kms from the Southern of Nha Trang
 - o breed testing animals serving research and quality control
 - o Raise horses for producing crude sera
 - o Produce food for cattle, microorganism fertilizer

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
BCG vaccine	Freeze dried vaccine against tuberculosis	Ampoule	10 doses/ampoule
DPT vaccine	Combination vaccines against diphtheria, pertussis and tetanus	Vial	10ml/vial
TT vaccine	vaccine composed of inactivated tetanus toxins - Multidose	Vial	10ml/vial
TT vaccine	vaccine composed of inactivated tetanus toxins - monodose	Ampoule	0.5ml/ampoule
SAT	Anti tetanus serum	Ampoule	1500IU/ampoule 1000IU/ampoule
SAR	Equine rabies immune globulin	Vial	1000IU/vial
SAV (SAV-naja ; SAV-tri)	Purified naja kaouthia antivenin and Purified trimeresurus albolabris antivenin	Vial	1000 LD50/vial
Im.BCG	BCG immunotherapy of bladder cancer	Ampoule	37.5mg/ampoule
Superferon	Interferon - 2b	Vial	3000000IU/vial

Future Product Pipe Line

- Pandemic Inactivated Monovalent Influenza Vacine (A/H5N1, A/H1N1, A/H7N9)
- Seasonal Splitted Trivalent Influenza Vaccine
- Acellular Pertussis Vaccine


Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
A/H1N1 Influenza vaccine					
A/H5N1 Influenza vaccine					
A/H7N9 Influenza vaccine					
Seasonal Splitted Trivalent Influenza Vaccine					

Areas of Interest for Collaboration

- Consolidate, upgrade , apply advanced technique for main products of IVAC:
acellular pertussis vaccine, anti-serum, combo vaccines based on frame of DTP...etc
- Build up Suoi Dau breeding farm to be suitable for its potential.
- Upgrade testing animals: species, food, workshop, technical service, etc.
- Establish a laboratory room to meet the Good Laboratory Practice (GLP) standards
- Build the personnel organization based on new mechanism, agreeing with national strategy on local vaccine production.
- Join, and associate with both domestic and international institutes in researching on new products.
- Enhance both the quality and quantity of existing vaccines to progress exporting vaccines to foreign markets.
- Consolidate and upgrade the Quality Management system.
- Biologics, ie mAb, biosimilar, recombinant protein drugs

Contact Details

Name of contact person	: Dr. Le Kim Hoa	Phone	: +84 58 3 822 408; +84 58 3 818 898
Address	: 09 Pasteur St.	Mobile	: +84 90 3 504 198
City	: Nha Trang	Fax	: +84 58 3 823 815
State	: Khanh Hoa	email	: lekimhoa@dng.vnn.vn
Location	: Vietnam	Website	: www.ivac.com.vn
Postal code	: 084		



Name of the company : **Instituto Butantan**

Head of Institution : **Jorge Kalil**

Established : **1901**

Location : **Brazil**

Overview of the company

Instituto Butantan is one of the most prestigious public scientific institutions in Brazil and internationally recognized for its outstanding biomedical research, production of immunobiologicals (vaccines and hyper immune sera) and diffusion of technical-scientific knowledge. The mission of the institution is to investigate, develop, manufacturer, and delivery high quality immunobiological products free of charge to the Brazilian population through the National Immunization Program / Ministry of Health. Instituto Butantan is currently responsible for the production of 40% of Brazil's sera and vaccines. In order to keep contributing with the Brazilian immunobiological self-sufficiency program and to improve nationally and internationally public health the Institute has strongly invested in internal R&D program, establishment of partnerships with national/international research institutions, and programs aiming at the incorporation of new technologies (Butantan and private companies partnerships). The Instituto Butantan has recently launched an internal preparation program aiming at the pre-qualification of its vaccines by World Health Organization. This initiative confirms the commitment of the Instituto to contribute not only to the Brazilian public health but also to the world.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Seasonal influenza vaccine	influenza trivalent vaccine (split and inactivated)	Vial	5ml
DTP	diphtheria, tetanus and pertussis (cellular) adsorbed vaccine (DTP)	Vial	5ml
dT	diphtheria y tetanus adsorbed vaccine (dT) - adults	Vial	5ml
DT	diphtheria y tetanus adsorbed vaccine (DT) - pediatric	Vial	5ml
Rabies	human rabies vaccine (inactivated)	Vial	1ml
Hepatitis B	adsorbed hepatitis B vaccine (recombinant)	Vial	5ml
HPV	recombinant	Vial	0.5ml

Future Product Pipe Line

- Tetravalent Dengue Vaccine
- Pertussis Low (cellular pertussis)
- Pentavalent Rotavirus Vaccine
- BCG-pertussis + HepB
- Onco-BCG (recombinant)
- Pneumococcal (cellular)
- 2nd Generation of Surfactant (porcine origin)
- Monoclonal antibodies
- dTap
- HPV (tetravalent)
- Hepatitis A
- Adjuvant Monophosphoryl Lipid A
- Adjuvant Silica

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Tetravalent dengue vaccine					2017/2018
Pertussis Low					2020
Pentavalent Rotavirus Vaccine					2020
BCG-pertussis + HepB					To be defined
Onco-BCG (recombinant)					
Pneumococcal (cellular)					To be defined
2nd Generation of Surfactant (porcine origin)					To be defined
Monoclonal antibodies	Technology Transfer Program (Libbs) rituximabe – Phase III clinical trial – expected launch 2017 bevacizumabe – Phase I clinical trial completed – expected launch 2021				
dTap	Technology Transfer Program (dT from Butantan and ap from GSK)				
Hepatitis A	Technology Transfer Program (MSD)				
HPV	Technology Transfer Program (MSD)				
Adjuvant Silica					To be defined
Adjuvant Monophosphoryl Lipid A					2020

Areas of Interest for Collaboration

- Combo vaccines
- Adjuvants
- Clinical Trials

Contact Details

Name of contact person : **Alexander Precioso**
 Address : **Avenida Vital Brasil 1500**
 City : **Sao Paulo**
 State : **Sao Paulo**
 Location : **Brazil**
 Postal code : **05503-900**

Phone : **+55-11 2627 9372**
 Mobile : **+55-11 99644 7132**
 Fax : **+55-11 2627 9507**
 email :
 Website : **www.butantan.gov.br**



Name of the company : **Institute of Medical Biology,
Chinese Academy of Medical Sciences**

Head of Institution : **Dr. Li Qihan**

Established : **1958**

Location : **P.R. China**

Overview of the company

The Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) was founded in 1958, and it integrates basic medical research with the development and production of biological products. It is mainly involved in basic and applied research in the following fields: medical virology, immunology, genetics, molecular epidemiology, experimental zoology using primates and large-scale production of vaccines as well as immunological and genetic engineering products.

IMBCAMS is the oldest and largest research and production base for a series of poliomyelitis and hepatitis A vaccines, which has made great contributions to the control and eradication of poliomyelitis and played an essential role in decreasing the incidence of hepatitis A in China.



Prior to the solid theoretical base, rich research accumulation and professional talent teams gradually developed in the past over 50 years, IMBCAMS has accumulated an solid and extensive basis for applied basic research and development of new products, and has established an independent innovation system for vaccine research and development. According to the requirements of national infectious disease prevention and control system, the new vaccine of Inactivated Poliomyelitis Vaccinemade from attenuated Sabin strains,Inactivated Enterovirus 71 Vaccine, etc, arecontinue to be licensed in the future.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
	Oral Live Attenuated Poliomyelitis Vaccine in dragee candy	Pill	1.0g
	Oral Live Attenuated Poliomyelitis Vaccine	Vial	1.0ml
Weisairuji	Hepatitis A (Live) Vaccine, Freeze-dried	Ampoule	1.0ml
Aibiwei	Inactivated Poliomyelitis Vaccine Made From Sabin Strains	Ampoule	0.5ml

Future Product Pipe Line

- Enterovirus Type 71 Vaccine,Inactivated (Human Diploid cell)
- Inactivated Influenza Virus Virolysis Vaccine
- Inactivated Japanese Encephalitis Purified Vaccine
- bOPV 1&3
- F-genotype Attenuated Mumps Vaccine
- Rabies Vaccine(Human Diploid cell)
- DTaP-sIPV Combined Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Enterovirus Type 71 Vaccine,Inactivated (Human Diploid cell)					2015
Inactivated Influenza Virus Virolysis Vaccine					2016
Inactivated Japanese Encephalitis Purified Vaccine					
bOPV 1&3					
F-genotype Attenuated Mumps Vaccine					
Rabies Vaccine(Human Diploid cell)					
DTaP-sIPV Combined Vaccine					

Areas of Interest for Collaboration

- Product export
- Vaccine development
- WHO pre-qualification

Contact Details

Name of contact person	: Dr. Shi Li	Phone	: +86 871 6833 5402
Address	: 935# Jiaoling Road, Kunming, Yunnan Province, P.R. China	Mobile	: +86 1388 8161 019
City	: Kunming	Fax	: +86 871 6833 4483
State	: Yunnan	email	: shili@imbcams.com.cn
Location	: P.R. China	Website	: www.imbcams.ac.cn
Postal code	: 650-118		





Name of the company : **Laboratorios de Biológicos y Reactivos de México, S.A. de C.V. (BIRMEX)**

Head of Institution : **Luis Guillermo Ibarra Ponce de León**

Established : **in Mexico City since 1999. Birmex as an enterprise started in 1999 but, as part of the Ministry of Health, has over 100 years producing vaccines.**

Location : **Mexico**

Overview of the company

Birmex is a government-owned company that produces imports and commercializes vaccines, antivenoms and biological reagents.

Our personnel possess a vast expertise in biologics production, which combines with a stringent quality control of the production procedures. This expertise results in the successful updating of facilities, production procedures, and programs aimed to meet Good Manufacturing Practices as certified by the National Regulatory Agency.

Over the years, Birmex has evolved into a reliable guarantee of experience and know-how for its customers, incorporating into each product and service:

- The confidence of high quality
- The pledge of an end-to-end service with full tracking and control over shipments at all times, whether by land or air
- The security of on-time distribution to any point in the country - this because Birmex is the only laboratory that delivers to all Mexico's 32 states
- The innovation, competitiveness, honesty and integrity in each process focused on offering solutions that meet the customer's needs
- And finally, the assurance of being with a laboratory whose experience, market knowledge and degree of specialization today make it the leading vaccine manufacturer in Mexico and one of the three principal vaccine manufacturing countries in Latin America



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
tOPV	Trivalent Sabin Oral Polio Vaccine	Dropper	2.0 ml (20 doses)
Td vaccine	Tetanus and Diphtheriattoxoids for adult	Vial	5.0 ml (10 doses)
Snake Antivenom	Freeze-dried to be reconstituted with 10 mL of Water for Injection as diluent This serum is made with venoms from the species <i>Crotalus basiliscus</i> and <i>Bothrops asper</i> , and it has also cross-reaction against venoms of the genus <i>Agkistrodon</i> and <i>Sistrurus</i>	Vial	10.0 ml (1 dose)
Scorpion Antivenom	Freeze-dried to be reconstituted with 5 mL of Water for Injection as diluent This serum is made with venoms from the genus <i>Centruroides</i> .	Vial	5.0 ml (1 dose)

Future Product Pipe Line

- Bivalent Oral Polio Vaccine (Types 1 and 3)
- DPwT with whole cell pertussis vaccine
- Tdpa with acelular pertussis vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Bivalent Oral Polio Vaccine (Types 1 and 3).					Q3 / 2016
DPwT					Q4 / 2017
Tdpa					Q4 / 2017

Areas of Interest for Collaboration

- Cell-culture based vaccines
- Scale-up process
- Plant design (industrial and pilot level)
- Technology transfer for vaccine production
- From bench to patient, vaccine development
- Rotavirus vaccine. Technology transfer
- Development and scaling up conjugated vaccines
- Characterization of snake venoms
- Characterization of scorpion venoms
- Purification of antivenoms

Contact Details

Name of contact person	: Sonia Villaseñor Bustamante International Business Manager	Phone	: +52-55 5422 2873
Address	: Lázaro Cárdenas Número 911, 8° piso, Colonia Vertiz Narvarte, Delegación Benito Juárez,	Mobile	:
City	: Mexico City	Fax	: +52-55 5422 2881
State	: D.F.	email	: svillasenor@birmex.gob.mx international@birmex.gob.mx
Location	: Mexico	Website	: www.birmex.gob.mx
Postal code	: 03600		



Name of the company : **LG Life Sciences Ltd.**

Head of Institution : **Il Jae Jung**

Established : **1947**

Location : **Republic of Korea**

Overview of the company

LG Life Sciences(LGLS) has developed and commercialized an array of pharmaceuticals for human and animal applications over the years. Especially for vaccines, LGLS successfully developed hepatitis B vaccine (EUVAX B™ Inj.) which has been exported to more than 80 countries through UN-sponsored programs and represented the major portion of overseas sales. Further to hepatitis B vaccine, LGLS successfully developed tetravalent DTP-based combined vaccines. These include DTaP-HepB(Eutravac™ Inj.) and DTwP-HepB(Euforvac™ Inj.). Both of them were approved by Korean FDA in

year 2008 and showed superior efficacy and safety. LGLS also developed a Hib vaccine(Euhib™ Inj.), as a component of pentavalent vaccine by reconstitution with DTwP-HepB-Hib(Euforvac-Hib™ Inj.). In addition, LGLS is developing a fully-liquid pentavalent vaccine(Eupenta™ Inj.), based on the accumulated technology and knowhow, for UN vaccine market. And year 2011, LGLS is selected by WHO as one of tech transfer recipient of sabin IPV. Based on this new technology, LGLS will continue to develop hexavalent and further combined vaccines. Through the long development history on vaccines LGLS accumulated a lot of experiences on vaccines and came to have very strong capability on vaccine development area. In the future, LGLS will remain a leader in life sciences and biotechnology-value added areas that are knowledge intensive.



Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Euvax B™Inj.	Recombinant Hepatitis B vaccine	Vial Liquid	0.5/1.0/5.0ml
Euforvac™Inj.	Adsorbed diphtheria, tetanus, whole cell pertussis & hepatitis B combined vaccine	Vial Liquid	0.5/1.0/5.0ml
Eutravac™Inj.	Adsorbed diphtheria, tetanus, acellular pertussis & hepatitis B combined vaccine	Vial Liquid	0.5ml
Euhib™Inj.	<i>Haemophilus influenzae</i> type b vaccine	Vial Lyophilized	0.5/1.0ml
Euforvac-Hib™Inj.	Adsorbed diphtheria, tetanus, whole cell pertussis, hepatitis B and <i>Haemophilus influenzae</i> type b combined vaccine	Vial Lyophilized	0.5/1.0ml

* More detailed information of LGLS' full list of current product pipeline & future product pipeline is available at www.lgls.com.

Future Product Pipe Line

Product Name	Pre	Clinical	Expected launch date		
	Phase 1	Phase 2	Phase 3	Quarter	Year
hGH					
EPO (Espogen®)					
SR-hGH(adult GHD)					
SR-hGH(Pediatric GHD)					
MAB(LBEC0101)					
MAB(LBIM0101)					
MAB(LBAL)					
DTwP-HepB-Hib (Fully liquid)					
sIPV(sabin strain)					
DTP-HepB-Hib-IPV(fully liquid)					
Cell culture influenza vaccine					
HA IDF 1(Skin Rejuvenation)					
HA IDF 2(Skin Rejuvenation)					
LBSA0103(Osteo Arthritis)					
Anti-Adhesion Barrier(Post Operation Adhesio)					

DS: Discovery, PC: Preclinical Studies, MKT: Market, GHD: Growth Hormone Deficiency, TS: Turner's Syndrom, CRI: Chronic Renal Insufficiency, SGA : Small for Gestational Age, SR : Sustained Released , CRF: Chronic Renal Failure, IVF: In vitro Fertilization, CML: Chronic Myeloid Leukemia, HA: Hyaluronic Acid, IDF: Injectable Dermal Filler

Areas of Interest for Collaboration

- Development and marketing partnership for novel vaccine products
- Marketing alliance for biologics, SR-hGH, EPO, rFSH, etc.
- Global marketing partnership or distributionship for HA based products
- Global marketing partnership or distributionship for Fative®

Contact Details

Name of contact person : Vaccine Biz.

Address : LG Gwanghwamun Bldg.
92, Sinmunno 2-ga, Jongno-gu

Phone : +82 0 2 6924 3147

City : Seoul

Mobile :

State :

Fax : +82 0 2 6924 3059

Location : Republic of Korea

email : kimhs@lgls.com

Postal code: 110-062

Website: www.lgls.com





Name of the company : **Liaoning Cheng Da Biotechnology Co., Ltd (CDBIO)**

Head of Institution : **Ms. Zhang XiaoHua**, General Manager

Established : **2002**

Location : **P.R. China**

Overview of the company

CDBIO is an integrated biotechnology company engaged in R&D, manufacturing, distribution and sales of vaccine products. In 2002, the company introduced world's leading technology platform---"bioreactor and micro-carrier cell culture technology"---, from which the company has developed rabies vaccine and Japanese Encephalitis vaccine.

Until now, our products have been distributed in almost all over the China as well as more than 15 countries in international

markets. According to the statistic data, totally more than 100 million doses of rabies vaccine for human use have been used for rabies prophylaxis during the last 7 years and there is no failure case reported after finishing the whole vaccination schedule. The inactivated Japanese Encephalitis vaccine (Vero cell) has also been launched since 2008 and now it has become a better choice for JE prevention. In 2012, the company built a new manufacturing facility following to the Current GMP regulations and it will come into use in 2013.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Rabies vaccine for human use	<ul style="list-style-type: none"> Perfusion Culture by Bioreactor and micro-carrier system Chromatographically Purified High Immunogenicity (>4.5IU/dose before lot release) High safety Preservative free, antibiotics free 	Vial	Liquid solution: 0.5ml/dose Lyophilized powder 0.5ml/dose after reconstitution
Rabies vaccine for veterinary use	<ul style="list-style-type: none"> Perfusion Culture by Bioreactor and micro-carrier system High Immunogenicity (2.0IU/dose) High safety Antibiotics free 	Vial	1ml/vial for one dose 5ml/vial for 5 doses
Inactivated Japanese Encephalitis Vaccine for human use	<ul style="list-style-type: none"> Perfusion Culture by Bioreactor and micro-carrier system Chromatographically Purified Preservative free, antibiotics free High safety High Immunogenicity 	Vial	Liquid solution: 0.5ml/dose Lyophilized powder 0.5ml/dose after reconstitution

Future Product Pipe Line

- Hemorrhagic Fever with Renal Syndrome Bivalent Vaccine
- Combined bacterial vaccine

Product Name	Pre Clinical		Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3		
Hemorrhagic Fever with Renal Syndrome Bivalent Vaccine						2014
Combined bacterial vaccine						2017

Areas of Interest for Collaboration

- We are seeking partnerships with large pharmaceutical company who are interested in developing biotech and vaccine products
- In-licensing Opportunity in China

Contact Details

Name of contact person : **Mr. Wu zhe**

Address : **No. 1, Xinfang Street, Hunnan New District**

City : **Shenyang**

State : **Liaoning Province**

Location : **P.R. China**

Postal code: **110179**

Phone : **+86-24-83787033**

Mobile: **+86-13109875430**

Fax : **+86-24-83787033**

email : **zhe66@hotmail.com**

Website: **www.cdbio.cn**



Name of the company : **Medigen Vaccine Biologics Co.**
 Head of Institution : **Dr. Stanley Chang (CEO/Chairman)**
 Established : **October 2012**
 Location : **Taiwan**

Overview of the company

Medigen Vaccine Biologics Co. (hereinafter as MVC), founded in 2012, is devoted to develop innovative cell-based vaccine with state-of-the-art cell-culture technologies and cost-effective production using single-use systems. MVC has successfully established cell-based platforms for pandemic influenza H5N1, H7N9, and Enterovirus 71 vaccines. Currently, H7N9 and Enterovirus 71 vaccines are at the clinical development.

Furthermore, to ensure adequate supply of high quality vaccines, MVC is establishing a first PIC/S GMP certified cell-based vaccine plant in Taiwan. The construction is estimated to be completed by the end of 2015, and pilot production is likely to be initiated in 2016. The designed production capacity is up to ten million doses per year. MVC commits not only to supply the vaccine for Taiwan people, but also provide vaccines globally to contribute to the human health care in the near future.



Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml

Future Product Pipe Line

- Enterovirus 71 (EV71) Vaccine
- Pandemic Influenza Vaccine (H1N1 & H5N1 & H7N9)
- Seasonal Influenza Vaccine
- Japanese Encephalitis Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
EV71 Vaccine					
H5N1 Influenza vaccine					
H7N9 Influenza vaccine					

Areas of Interest for Collaboration

- Joint development for novel cell-based vaccines& biologics
- Marketing and distribution of vaccines& biologics
- In licensing / out licensing
- Biologics, ie mAb, biosimilar, recombinant protein drugs

Contact Details

Name of contact person	: Dr. Ting-Wan Lin	Phone	: +886-2-77 450 830
Address	: 7F., No.16, Ln.120,Sec. 1, Neihu Rd.,	Mobile	:
City	: Taipei	Fax	: +886-2-26 588 980
State	: Khanh Hoa	email	: info@medigenvac.com
Location	: Taiwan	Website	: www.medigenvac.com
Postal code	: 11493		





Name of the company : **National Administration of Laboratories & Institutes of Health Anlis “Dr. Carlos G. Malbrán”**

Head of Institution : **Dr. Gustavo Ríos**

Established : **1996**

Location : **Argentina**

Overview of the company

The National Administration of Laboratories and Institutes of Health ANLIS “Dr. Carlos G. Malbrán” agency dependent of The Secretary of Policy, Regulation and Institutes of the Ministry of Health of Argentine Nation nucleates eleven institutes and centers located in different places in our country (all of them of recognized performance in their areas of competence).

Its fundamental function understands in science and technical policy associated with various substantive aspects of actions in public health. The Institutional Plan recognizes 6 strategic areas:

1. Research and Technological Development in Health.
2. Health Surveillance and outbreak control.
3. Prevention and Control Disease Programs.
- 4. Production and Supply of Health Strategic Inputs.**
5. Education and Training of Health Human Resources.
6. Information and Communication in Health.

Planned activities in the Production and Supply of Strategic Inputs Area will focus to achieve more equitable access (regarding availability and prices) to technologies and essential medical supplies, with guaranteed quality, safety, effectiveness and cost effectiveness and to promote reasonable and effective use according to their costs.

The global products portfolio of interest includes: viral and bacterial vaccines, immunotherapies (antidotes and antitoxins sera), diagnosis kits and reagents, inputs for reference and proficiency tests sera panels and reference biological standards, biopharmaceuticals and strategic medicines and laboratory animals.

Current Product Pipeline

Product Name		Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Candid # 1		Virus Junin live attenuated vaccine against Argentine Hemorrhagic Fever	10 doses Vial	Lyophilized
Viper venom antiserum, Bothrops bivalent			vial	10.0 ml
Viper venom antiserum, Bothrops tetravalent			vial	10.0 ml
Viper venom antiserum, Crotalus durissus terrificus			vial	10.0 ml
Viper venom antiserum, Micrurus pyrrhocryptus			vial	5.0 ml
Spider venom antiserum, Loxosceles SP			vial	5.0 ml
Spider venom antiserum, Latrodectus SP			vial	2.0 ml
Scorpion venom antiserum, Tityus trivitattus			vial	2.0 ml
Rabies vaccine, FP, human use			vial	2.0 ml
Rabies vaccine, FP, veterinary use			vial (multidose)	50.0 ml
Tuberculin purified protein derivate, human use			vial (multidose)	3.0 ml
BCG for immunotherapy			vial	5.0 ml
Serotyping antisera (Enterobacteriaceae & Vibrio cholerae)			vial	Miscellaneous volumes
Tetanus toxoid – API			N/A	N/A
Diphtheria toxoid – API			N/A	N/A
Pertussis (cellular component) – API			N/A	N/A

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Yellow Fever Vaccine					Implementation of a Quality System training to staff ANLIS in Argentina November 2011
dT vaccine – Diphteria and Tetanus vaccine					Adaptation, renovation and design of the productive areas of the components or API's (used to produce DTP and dT) and acquisition of necessary equipment and instrumentation Execution of the work of the filling and packaging plant and submission a file that includes all equipment and instruments needed in the plant. 2011
DTP vaccine – Diphteria, Tetanus and Pertussis vaccine					
Pentavalent vaccine DTP-HB/Hib					In technology transference management

Kits for diagnosis use: Rotavirus, *Neisseria meningitidis*, *Streptococcus pneumoniae*, Toxoplasmosis, Chagas, Leptospirosis, Brucellosis, etc.

Areas of Interest for Collaboration

- Production technologies
- Quality Control
- Quality Assurance
- Management
- Good Manufacturing Practices
- Clinical trials
- Ethical issues
- Vaccine development
- Vaccine patents politics
- Regulatory issues

Contact Details

Name of contact person : **Flavia M. Consalvo**

Address : **Av. Vélez Sarsfield N° 563**

Phone : **+54 011 4303 1804 ext. 159**

City : **Ciudad Autónoma de Buenos Aires**

Mobile : **+54 011 5594-5332**

State : **Ciudad Autónoma de Buenos Aires**

Fax : **+54 011 4303 1804**

Location : **Argentina**

email : **fconsalvo@anlis.gov.ar**

Postal code: **C1282AFF**

Website: **www.anlis.gov.ar**



Name of the company : **National Institute of Infectious Diseases and Vaccinology**

Head of Institution : **Ching-Len Liao, Ph.D**

Established : **May 2011**

Location : **Taiwan**

Overview of the company

The National Institute of Infectious Diseases and Vaccinology (NIIDV) is a mission-oriented R&D department within the National Health Research Institutes (NHRI) in Taiwan, a non-profit organization established by Taiwan government.

NIIDV was formally established in May 2011 by merging the Division of Infectious Diseases and the Vaccine R&D Center. NIIDV conducts researches on important infectious diseases and advocates for government actions and recommendations to solve healthcare problems. International collaborations are part of NIIDV's endeavors to deal with global infectious diseases. NIIDV has state-of-the-art technology, cGMP facility and expertise to develop novel vaccines and immunotherapeutics.



NIIDV has completed the phase I clinical trial of the MDCK cell-based H5N1 flu vaccines in 2010 and transferred to a local biotech company. The influenza vaccine (H5N1, H7N9) is prepared for phase II trials in 2013. The Vero cell-based EV71 vaccine was also developed and the phase I clinical trial has been completed in 2012. The meningococcal B recombinant vaccine is developed and going into phase I clinical trial. To meet national health needs, the BCG vaccine is manufacturing and going to be launched in 2015.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
BCG	Technology and product transfer from Taiwan CDC to be launched in 2015. Live freeze - dried BCG vaccine, 30 doses	Ampoule	3 ml
Antivenin	Technology and product transfer from Taiwan CDC to be launched in 2016.	Vial	30 ml
ProVEU	Cell-based flu vaccine	Vial	3 ml
Ev71vac	Cell-based flu EV71 vaccine	Vial	3 ml
MenBvac	Liporprotein-based meningococcal vaccine	Vial	3 ml

Future Product Pipe Line

- Adenovector-based RSV vaccine
 - HPV therapeutic vaccine
 - Recombinant BCG
 - Dengue vaccine
- Influenza vaccine (H7N9, etc.)
 - Bivalent vaccine against hand-mouth-foot disease

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Adenovector-based RSV vaccine					
HPV therapeutic vaccine					
Recombinant BCG					
Dengue vaccine					
Influenza vaccine (H7N9, etc.)					
Bivalent vaccine against hand-mouth-foot disease					

Areas of Interest for Collaboration

- Technology transfer cell-based viral vaccines and lipoprotein technology
- Service contract for GMP Filling and packaging
- Co-development of new vaccines
- Global marketing partnership/distributorship
- Licensing out of vaccine products and platform technology

Contact Details

Name of contact person : Ms. Amanda Tsao

Address : NO 35, Keyan Road, Zhunan Towan

Phone : +886-37-246166 ext.37856

City : Miaoli County

Mobile :

State :

Fax : +886-37-583009

Location : Taiwan

email : pmo@nhri.org.tw

Postal code: 35053

Website: www.nhri.org.tw



Name of the company : **Panacea Biotec Limited (PBL)**

Head of Institution : **Dr. Rajesh Jain, Ph.D.,**

Established : **February 1984**

Location : **India**

Overview of the company

Panacea Biotec is India's leading health management company with established research, manufacturing and marketing capabilities. Company has been amongst the top 40 biotechnology companies (BioSpectrum – ABLE Survey, July 2014) and the top 60 pharmaceutical companies (AIOCD AWACS – MAT May 2014) in India.

Panacea Biotec has been among the leading suppliers of vaccines to UNICEF and Government of India's with a focus on critical pediatric vaccines. Panacea Biotec has developed some vaccines first time in the world including the fully liquid pentavalent vaccine DTP-HepB-Hib (EasyfiveTT), Bivalent Oral Polio vaccine (OPV), Monovalent OPVs Type 1 & Type 3. Pharmaceuticals business is focused on super speciality, acute and chronic care segments mainly organ transplantation, renal diseases, diabetes, oncology, pain management, orthopedics and gastro-intestinal. The company has collaborations and tie-ups with leading national and international organizations. The company's state of the art manufacturing facilities comply



with US-FDA, UK-MHRA, SA-MCC and WHO-CGMP standards. The company is R&D focused with 4 state-of-the-art R&D centers focusing on vaccines, biosimilars, chemistry and biotechnology based drug discovery, novel drug delivery systems and "high barrier to entry" generics. The company has over 2700 employees including over 100 highly skilled scientists.

The Company's bulk vaccine and antigen manufacturing facility is located in city Lalru, State of Punjab (India) for manufacture of Recombinant, Bacterial, Viral Vaccines (bulk and antigens).

The Company's state-of-the-art vaccine formulation and filling facility is located at Baddi in Himachal Pradesh. This plant has been approved by WHO for EasyfiveTT.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/ Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
EasyFiveTT	DTP-HepB-Hib fully liquid Pentavalent Vaccine	Glass Vial, Glass PFS	SDV, MDV (10 Dose), Pre-filled Syringe (PFS)
Polprotec	Poliomyelitis inactivated vaccine	Glass Vial, Glass PFS	SDV, PFS
Oral Polio Vaccine	Poliomyelitis vaccine including monovalent Type1 and 3	Glass Vial	MDV (20 Dose)
Enivac HB	Recombinant Hepatitis B Surface Antigen Vaccine	Glass Vial	SDV& MDV (10 Dose)
NovoHib	Haemophilus Type b conjugate (PRP-TT)	Glass PFS	PFS
Pandyflu	Inactivated H1N1 vaccine	Glass Vial	MDV (10 Dose)
PacliAll	First Nano particle paclitaxel product in India	Glass Vial	Vial
Pangraf	Tacrolimus	Blister Pack, HDPE bottle	Capsule
Mycept	Mycophenolate Mofetil	Blister Pack	Tablet
Glizid	Gliclazide (Pain and Combinations)	Blister Pack	Tablet
Sitcom	Euphorbia Prostrata Extract (Plain and Combinations)	Blister pack, Tube	Tablet and Cream

Overall, PBL currently has more than 90 brands in its pharmaceutical wing spanning across various therapeutic segments and in different countries (Regulated as well as Non-regulated markets).

Future Product Pipe Line

Vaccine

- Dengue recombinant Tetravalent lyophilized vaccine
- EasyFour TT (DTP-Hib), fully liquid Tetravalent vaccine
- EasySix (DTP-HepB-Hib-IPV) fully liquid Hexavalent vaccine
- Pneumococcal Conjugate vaccine (10-valent), liquid vaccine
- Japanese Encephalitis (JE)
- Conjugated Meningococcal Vaccine
- Seasonal Flu
- sIPV based Vaccines

Pharmaceuticals

○ Alliance for high end Anti-Cancer Products

- The company has entered into a strategic alliance with Apotex Inc. for development, license and supply of two anti-cancer generic products based on nano-particle & liposomal technology for US, Canada, Australia and New Zealand markets.

○ New Products:

- Currently 5 ANDA products with high business potential (in Anti-cancer,CNS, CVS therapy area) are under registration in US which are expected to be commercialized in the coming years. In addition a range of generic products (with high market potential, high developmental barrier and less potential competition) are under development from Immuno-suppression, anti-cancer, ESRD therapies.
- The company has commercialized Tacpan (Tacrolimus) &Mowell (Mycophenolate) through its indirect WOS - Panacea Biotec Germany GmbH.
- Panacea Biotec (International) SA ("PBS") a wholly owned subsidiary based out of Switzerland, a strategic business outfit of the company, has come a long way since its incept, establishing itself in the highly regulated markets like Australia, New Zealand

Product Name	Pre Clinical		Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3		
EasyFour TT (DTP-Hib)						2016
EasySix (DTP-HepB-Hib-IPV)						2016
Pneumococcal Conjugate vaccine (10-valent)						
Dengue						2017

Areas of Interest for Collaboration

- Human Papiloma Virus (HPV) Vaccine
- Rotavirus Vaccine
- Conjugate Typhoid Vaccine

Contact Details

Name of contact person	: Dr. Rajesh Jain, Ph.D.	Phone	: +91 11 41679035
Address	: B-1 Extn./A-27, Mohan Co-op. Industrial Estate, Mathura Road	Mobile	:
City	: New Delhi	Fax	: +91 11 26940621
State	: New Delhi	email	: rajeshjain@panaceabiotec.com
Location	: India	Website	: www.panacea-biotec.com
Postal code	: 110 044		



Name of the company : **Production & Research Complex for Pasteur Institute of IRAN**

Head of Institution : **Dr.Hooman Kaghazian, Ph.D.,**

Established : **March 1987**

Location : **IR of Iran**

Overview of the company

Located in the heart of Tehran, Pasteur Institute of Iran (PII) has been providing health care services and related products to the public since 1920. The initial goal of PII establishment was to recognize and combat domestic infectious diseases. PII now is the home of different departments and research centers such as Bacteriology, Biotechnology, Genetics, Parasitology & Mycology, Clinics, and Virology. PII has also been involved in manufacturing a number of parenteral fluids for hospital use since its establishment.

To meet increasing domestic demand PII manufacturing part moved to a new place in outskirts of Tehran in 1988 and assigned as “Production and Research Complex (PRC)”. In the new place PII was successfully able to develop its manufactures to varieties of product. Currently PRC productions fall

into three categories:

Vaccines: such as Hepatitis B, BCG, and Anti-Rabies (for veterinary use).

Recombinant Protein Preparations: such as Erythropoietin, Interferon alfa 2b, and Streptokinase. Parenteral fluids.

Therapeutics such as intravesical BCG.

Diagnostic materials used in Medical Laboratories.

Equipped with state-of-the-art machineries PRC now is one of the leading companies in manufacturing biopharmaceuticals in the country and the region.

PRC also benefits from quality assurance (QA) and quality control (QC) departments with close cooperation of the National Regulatory Authorities (NRA).

PRC vision is to employ innovative technologies in order to expand its GMP-oriented products to meet domestic demands as well as looking into foreign markets. In order to commercialize products outside the country, PRC recently applied for pre-qualification status through WHO for its vaccines.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hepatitis B Vaccine (Rec.)	Liquid	Vial	5.0 (10 doses)
BCG Vaccine	Lyophilized	Vial	2.0 (20 doses)
Rabies Vaccine (for animal use)	Liquid	Vial	1.0 (1 dose)
BCG Intravesical (Immune)	Liquid	Vial	120mg/3ml
Erythropoietin (Rec.)	Liquid	Vial	1.0 (2000 I.U.)
Parenteral Solutions	liquid	Vial	50
Diagnostic Kits	Antigens & Antiserums Culture	Vial	
Experimental Animals	Mice- Rabbits- Guinea Pigs- Hamster		

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Interferon Alfa 2b					2014
Streptokinase (Rec.)					2014
Rabies vaccine (for Human use)					2015
MMR Vaccine					
Opaque Agents					
Sodium Bicarbonate					
Pentavalent Vaccine					
Pentaperazole					
Anti Venoms (Snakes & Scorpions)					
Hepatitis B (New Version)					2015
Immunological Diagnostic Kits					
Parenteral Amino Acids Solutions					
PEG Interferon					
VZV Vaccine					
Influenza Vaccine					
Meningitis Vaccine					
Pneumococcal Vaccine					
Hepatitis E Vaccine					
Malaria Vaccine					

Areas of Interest for Collaboration

- Recombinant Biopharmaceuticals
- Cell-Culture-Based Vaccines
- Co Operated Manufacturing
- Vaccine Technology Transfer
- Quality Control, Quality Assurance

Contact Details

Name of contact person : **Vahid Marandi**

Address : **25th Kilometer of Tehran-Karaj Highway**

Phone : **+98 26 36100978**

City : **Karaj**

Mobile :

State : **Alborz**

Fax : **+98 26 3612900**

Location : **IR of Iran**

email : **vahid_marandi@pasteur.ac.ir**

Postal code: **3159915111**

Website: **http://www.pasteur.ac.ir**



Name of the company : **Queen Saovabha Memorial Institute, The Thai Red Cross Society**

Head of Institution : **Prof. Dr. Visith Sitprija**, Director

: **Prof. Dr. Sumana Khomvilai**, Deputy Director

Established : **1922**

Location : **Thailand**

Overview of the company

The Queen Saovabha Memorial Institute (QSMI), founded in 1922, has its mission in producing vaccines and snake antivenoms and conducting research on snakes, snake venoms, rabies and related topics.

QSMI established a snake farm in 1923 and a horse farm in 1956. QSMI has been manufacturing snake antivenoms since 1923, BCG vaccine since 1953 and rabies immunoglobulins since 2002. Work on snakes, snake antivenoms, rabies and equine rabies immunoglobulin has gained international reputation for many decades. The horse farm has more than 500 horses. The Institute is recognized by WHO as WHO Collaborating Centres in both rabies and snake work. The activities of Queen Saovabha Memorial Institute cover 3 main areas of service, research and production as follows.

I. Service

1. Treatment of animal bites and vaccination against rabies
2. Animal clinic and Rabies diagnosis
3. Travelers immunization clinic
4. Other immunization
5. Snake farm for public



6. Joint collaborative projects in clinical and laboratory diagnosis of human and animal suspect of being rabid, route of rabies vaccine administration (with ministry of public health, livestock department, WHO and US communicable disease center).

II. Research and Development

1. Research for improvement of product and diagnosis
2. Biomedical and clinical research in areas of Rabies, snakes, snake venoms and horses
3. Collaboration and joint research projects between QSMI and other educational and research institute
4. Future plan: New tuberculosis vaccine

III. Production

- Biological products as indicated in Current Product Pipeline
- Antidote for the government (Sodium nitrite, Sodium thiosulfate and Methylene blue injection)

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
BCG Vaccine			
Rabies vaccine	lyophilized product of 10 doses per vial	vial	0.5 ml
(TRCS Speeda)			
Equine rabies	lyophilized product of 1 doses per vial	vial	0.5 ml
immunoglobulins	injection liquid of 1,000 IU per vial	vial	5.0 ml
(TRCS ERIG)			
Antivenoms for poisonous snake bite			
- King Cobra antivenin (<i>Ophiophagus Hannah</i>)			
- Cobra antivenin (<i>Naja Kaouthia</i>)			
- Banded Krait antivenin (<i>Bungarus fasciatus</i>)			
- Malayan Pit Viper antivenin (<i>Calloselasma rhodostoma</i>)			
- Russell's Viper antivenin (<i>Daboia russellii siamensis</i>)			
- Green Pit Viper antivenin (<i>Trimeresurus albolabris</i>)			
- Malayan Krait antivenin (<i>Bungarus candidus</i>)			
- Neuro polyvalent antivenin (<i>Naja kaouthia</i> , <i>Ophiophagus hannah</i> , <i>Bungarus fasciatus</i> and <i>Bungarus candidus</i>)			
- Haemato polyvalent antivenin (<i>Calloselasma rhodostoma</i> , <i>Trimeresurus albolabris</i> , <i>Daboia russellii siamensis</i>)			
	lyophilized product in 20 ml. vial with solvent of Water for injection 10 ml.	vial	10.0 ml

Future Product Pipe Line

(imported bulk vaccine for formulation and filling) : Estimate launch in year 2016-2017

- **Influenza** : injection liquid 1 ml per vial of 2 doses
- **JE vaccines** : lyophilized product of 0.5 ml per vial
- **Td vaccines** : injection liquid suspension of 2 ml per vial of 2 doses

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Influenza vaccine					Q4/2016
JE vaccines					Q4/2016
Td vaccines					Q4/2017

- New TB vaccine

Contact Details

Name of contact person	: Prof. Dr. VisithSitprija and Prof. Dr.SumanaKhomvilai	Phone	: +662 2520131
Address	:	Mobile	: Prof. Dr. VisithSitprija : 089 8401303 Prof. Dr. SumanaKhomvilai :061 5955959
City	: Bangkok	Fax	: +662 2540212
State	: Thailand	email	: visithstprj@yahoo.com sumanaredcross@gmail.com
Location	:	Website	: www.saovabha.co.th
Postal code	: 10330		



Name of the company : **Razi Vaccine & Serum Research Institute**

Head of Institution : **Dr. Hamid Kohram**

Established : **1925**

Location : **IR of Iran**

Overview of the company

Razi Vaccine and Serum Research Institute is known as one of the oldest and most reputed scientific centers in the Middle East. This institute began its activities in the year 1925 with producing vaccine against Rinderpest, which at the time had caused large casualties in the cattle population of the country. At present Razi institute is producing more than 60 biological products including human and veterinary vaccines, sera, etc.

Razi institute is governed by a Board of Trustees. The local costumers of the institute products are the Ministry of Health and the Veterinary Organization of the country. The institute is headquartered in the city of Karaj and has six branches in the cities Mashahad, Ahwaz, Shiraz, Marand, Kerman and Arak. These branches are mainly involved in the production of poultry and other veterinary vaccines.



The Institute is considered a center of research, training and technical assistance for vaccine production and is ready for providing its services and fulfilling the vaccine needs of other developing and neighboring countries.

The objectives are:

- + Research & Production of Medical Vaccines and Antisera
- + Research & Diagnosis of Veterinary and Poultry Diseases
- + Research & Production of Veterinary and Poultry Vaccines
- + Research and Diagnosis of Zoonotic Diseases
- + Biotechnology Research
- + Education & Training

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Trivalent DTP,dT, Td	Diphtheria-Tetanus-Pertussis Vaccines	Vial	14 doses/7ml
Measles	Live Attenuated vaccine (Lyo.)	Vial	10 doses/5 ml
Mumps, Rubella	Live Attenuated vaccines (Lyo.)	Vial	1 dose
bOPV	Live Attenuated vaccine	Flakon	15 doses/1.5 ml
Polio (type 1,2, and3)	Live Attenuated vaccine	Flakon	15 doses/1.5ml
MMR , MR, MM	Live Attenuated vaccines (Lyo.)	Vial	10 doses/5 ml
Polyvalent Snake Antivenom	Antivenom	Ampoule	10 , 5
Polyvalent Scorpion Antivenom	Antivenom	Ampoule	5
Anti-Tetanus Serum	Anti Toxin	Ampoule	2
Anti-Diphtheria Serum	Anti Toxin	Vial	5
Anthrax	Live vaccine	Bottle	100
Blackleg (Cattle)	Inactivated vaccine	Bottle	250
Polyvalent Enterotoxaemia (Sheep & Goat)	Inactivated vaccine	Bottle	250
Brucella Melitansis Strain Rev. 1	Live vaccine (Lyo.)	Vial	100
Brucella Abortus Strain IRIBA	Live vaccine (Lyo.)	Vial	20
Agalactia& Pasterulosis (Cattle & Buffalo)	Inactivated vaccines	Bottle	100
Tetanus (Horse)	vaccine	Vial	20
Rinderpest, Sheep Pox, Goat pox	Live vaccines (Lyo.)	Vial	100
Foot and Mouth Disease (FMD)	Inactivated vaccine	Bottle	250
Bovine Theileriosis	Attenuated vaccine	Vial	12
Fowl Cholera	Inactivated vaccine	Bottle	100
Fowl Pox	Live vaccine (Lyo.)	Vial	1000 , 2000
Infectious Laryngotracheitis	Live vaccine (Lyo.)	Vial	1000 , 2000
Fowl Infectious Bronchitis H-120& H-52	Live vaccines (Lyo.)	Vial	1000 , 2000
Newcastle La Sota, Newcastle B1	Live vaccines (Lyo.)	Vial	1000 , 2000,4000
Inactivated Influenza (oil-emulsion) H9N2	Inactivated vaccine	Bottle	250
Inactivated Newcastle (oil-emulsion) V4	Inactivated vaccine	Bottle	250
Combined oil-emulsion H9N2 & V4	Inactivated vaccine	Bottle	250
Combined IB (H-120) / ND (B1)	Live vaccine	Vial	2000

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Peste des Petits Ruminants (PPR)					Licensed & Produced
Combined Live IB (H-120) / ND (La Sota)					
Infectious Bursal Disease (IBD)					
Human Influenza Vaccine					
RS12					
Hib vaccine					
Tetavalent DTP-Hib					
Pentavalent DTP-Hib-HepB					
IPV					

Areas of Interest for Collaboration

- Training in the Fields of Production and QC Tests
- Production of New Recombinant Vaccines(Human, Poultry and Veterinary)

Contact Details

Name of contact person	: Dr. Hamid Kohram	Phone	: +91 982634554658
Address	: Razi Vaccine & Serum Research Institute Karaj	Mobile	:
City	: Karaj	Fax	: +91 982634554658
State	: Tehran	email	: int@rvsri.ac.ir
Location	: IR of Iran	Website	: www.rvsri.ac.ir
Postal code	: 3197619751		



Name of the company : **Serum Institute of India Ltd.,**
 Head of Institution : **Dr. Cyrus.S. Poonawalla,** Chairman & Managing Director
 Established : **1966**
 Location : **India**

Overview of the company

Serum Institute of India Ltd. (SII) founded in 1966 by a true visionary Dr. Cyrus Poonawalla, CMD, is now India's # 1 Biotech Company and the World's largest vaccine manufacturer (by number of doses) producing 1.3 billion doses a year of life saving vaccines. It is also one of the largest suppliers of WHO prequalified vaccines to U.N. Agencies catering to over 140 countries; and also recognized as a reliable largest source of high quality & affordable vaccines and biologicals. It is estimated that 2 out of every 3 children immunized globally get at least one vaccine produced by SII. SII is also the proud owner of Bilthoven



Biologicals, The Netherlands. SII is the only Indian company to feature in the top five vaccine companies (in terms of volume) among global giants GlaxoSmithKline, Merck, Novartis and Sanofi.

SII products are also registered in several countries including Switzerland. This impact has been large enough to make global agencies such as WHO, GAVI, PATH, NIH, NVI/RIVM, CBER/USFDA & BMGF to work with SII to develop newer vaccines. The production facilities of SII are the best in terms of equipment and human resources; essential to ensure high quality of vaccines. The manufacturing facilities conform to WHO cGMP requirements and till date SII's 21 vaccines are prequalified by WHO/Geneva.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
TT *	Tetanus Vaccine	Ampoule	Single dose (0.5 ml)
DT *	Diphtheria and Tetanus Vaccine (Paediatrics)	Vial	10 doses (5 ml)
Td *	Diphtheria and Tetanus Vaccine for Adults & Adolescents	Vial	20 doses (10 ml)
DTP *	Diphtheria-Tetanus-Pertussis Vaccine	Ampoule	1 & 2 doses (0.5/1 ml)
		Vial	10 & 20 doses (5/10 ml)
Q-Vac *	DTP and Hepatitis B Vaccine (Adsorbed)	Ampoule/Vial	0.5ml & 1 ml / 5 ml
Quadravax *	DTP + Hib Vaccine (Lyo. & Liquid)	Vial	0.5ml, 1 & 5 ml
Pentavalent *	DTP Hepatitis B + Hib Vaccine (Lyo. & Liquid)	Vial	0.5ml, 1, 5 & 10 ml
BCG *	BCG Vaccine	Vial	5ml, 10ml/ 10, 20 doses
Measles *	Measles Vaccine Live (Lyo.)	Vial	1, 2, 5 & 10 doses (0.5ml per dose)
Rubella *	Rubella Vaccine Live (Lyo.)		
MR *	Measles and Rubella Vaccine Live (Lyo.)		
MMR *	Measles, Mumps and Rubella Vaccine Live (Lyo.)		
Rabies *	Rabies Vaccine	Vial/Ampoule	1 ml / 1 dose
IPV	Inactivated Poliomyelitis Vaccine	Prefilled Syringe	0.5ml/dose
Nasovac *	Influenza Vaccine, Live Attenuated (Freeze-dried), Pandemic (H1N1)	Vial/Ampoule	1 & 2 doses (0.5ml per dose)
Hep B *	Recombinant Hepatitis B Vaccine (Pediatric & Adult)	Vial/Ampoule	0.5ml & 1ml
		Vial	5 & 10 ml
Hib *	Haemophilus type b Conjugate Vaccine (Lyo.)	Vial	1 dose
MenAfriVac *	Meningococcal A Conjugate Vaccine (Lyo.)	Vial	10 doses
bOPV *	Bivalent Oral Poliomyelitis Vaccine types 1 & 3	Vial	10 & 20 doses
tOPV *	Trivalent Oral Poliomyelitis Vaccine types 1, 2 & 3	Vial	10 & 20 doses
ATS	Tetanus Antitoxin	Ampoule/Vial	1 ml / 5 ml
ADS	Diphtheria Antitoxin	Vial	10 ml
ASVS	Anti-Snake Venom Serum (Lyo.) Asia & Central Africa	Vial	10 ml
ARS	Anti-Rabies Serum	Vial	5 ml

* Products prequalified by WHO for supplies to U.N. Agencies

Future Product Pipe Line

- DTaP vaccine
- Pneumococcal Polysaccharide Vaccine
- Rabies Monoclonal Antibody (RMab)
- Measles Vaccine (Dry Powder)
- Rabies vaccine (Verorab)
- Aerosol Measles vaccine
- Seasonal influenza Vaccine (Live attenuated)
- Rotavirus Vaccine (Lyophilized)
- Pentavalent Meningococcal Conjugate Vaccine (ACYWX)
- Human Papiloma Virus Vaccine (HPV)
- Recombinant BCG (rBCG) Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Newer Vaccines development
- Biosimilars
- Monoclonal antibodies

Contact Details

Name of contact person

: DR. SURESH S. JADHAV, Executive Director

Phone

: +91 20 2660 2378 / 2660 2978

Address

: 212/2, Hadapsar,Off Soli Poonawalla Road,
Hadapsar

Mobile

: +91 98230 22248

City

: Pune

Fax

: +91 20 2699 3945/ 2699 3921

State

: Maharashtra

email

: ssj@seruminstitute.com

Location

: India

Website

: www.seruminstitute.com

Postal code

: 411 028





Name of the company : **Sinergium Biotech**
 Head of Institution : **Alejandro Gil (CEO)**
 Established : **2009**
 Location : **Argentina**

Overview of the company

Sinergium Biotech is an Argentinean pharmaceutical company specialized in the research, development, production and commercialization of high-complexity vaccines and biological products.

The production complex, boasts a capacity of 20 million doses in a surface of 20,000m². Its equipment and production process standards are compatible with the highest international Good Manufacturing Practices (GMP), following the guidelines of U.S. regulatory agency Food & Drug Administration (FDA) and the European Medicines Agency (EMA).

In 2009, Sinergium Biotech entered into a technological transfer agreement for the production of seasonal and pandemic influenza virus vaccines. The production of influenza virus vaccines makes Argentina a member of the small group of countries

relying on their own technology to produce flu vaccine and thus to face possible pandemics.

In 2011, Sinergium Biotech formed an agreement with an international company for the technological transfer as well as the national production and provision of the pneumococcal conjugate vaccine. Sinergium Biotech also formulates packages and prepares for shipment active principles of monoclonal antibodies and others biological products.

Sinergium Biotech represents a great opportunity for international vaccine producers to develop their production capacity in Argentina and therefore set foot and expand their participation in the South-American region markets.



Current Product Pipeline

Product Name	Description	Type Vial/ Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Seasonal Flu	Anti-influenza Vaccine (inactivated surface antigens)	Prefilled Syringe	0.5 ml
Pediatric Seasonal Flu	Anti-influenza Vaccine (inactivated surface antigens)	Prefilled Syringe	0.25 ml
Adjuvanted Seasonal Flu	Anti-influenza Vaccine (adjuvant MF59C1)	Prefilled Syringe	0.5 ml
Pneumococcal Vaccine	Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)	Prefilled Syringe	0.5 ml
HPV Vaccine	Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18)	Prefilled Syringe	0.5 ml

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Technology Transfer for vaccine production
- Vaccine and biopharmaceutical Co-development
- Long Term partnership
- Product development and Process Innovation
- Marketing and Distribution of vaccines in Argentina and South America
- Vaccine joint development and R&D collaborations
- New Antigens and adjuvants
- Contract Manufacturing
- Fill and secondary packaging

Contact Details

Name of contact person

: Fernando Lobos

Address

: RutaPanamericana km 38.7

City

: Garin

State

: Buenos Aires

Location

: Argentina

Postal code

: B1619IEA

Phone

: +54 11 3220 7300 int 7307

Mobile

: +54 91158730862

Fax

:

email

: fernando.lobos@sinergiumbiotech.com

Website

: www.sinergiumbiotech.com





Name of the company : **Sinovac Biotech Ltd.**

Head of Institution : **Weidong Yin**

Established : **2001**

Location : **P.R. China**

Overview of the company

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuant to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine.



Sinovac has a robust pipeline of new vaccine products under development. The Company is currently developing vaccines for Enterovirus 71 (EV 71), Pneumococcal Conjugate Vaccine, Hib, and Meningitis. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for an independently developed inactivated animal rabies vaccine.

Sinovac is open and flexible to discuss any possible collaborative opportunity of international business and has established a clear path to partnering. We are seeking the partners who share the same value as ours

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Healive®	Inactivated Hepatitis A Vaccine	Vial	0.5, 1.0 ml
Anflu	Split Influenza Vaccine	Vial	0.25, 0.5 ml
Bilive	Hepatitis A and B Combined Vaccine	Vial	0.5, 1.0 ml
PANFLU.1	H1N1 Influenza Vaccine (Split virion)	Ampoule	0.5, 1.0 ml
H5N1	H5N1 Influenza Vaccine (Split virion)	Ampoule	0.5, 1.0 ml
H5N1	H5N1 Influenza Vaccine (Whole virion)	Ampoule	0.5, 1.0 ml
Mumps	Live attenuated vaccine	Vial	0.5ml

Future Product Pipe Line

- EV71 Vaccine
- Human Rabies Vaccine
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
- HIB Vaccine
- DTaP Vaccine
- HepB Vaccine
- Rotavirus Vaccine
- CA16 Vaccine
- Varicella Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
EV71 Vaccine					Q2/2014
Human Rabies Vaccine					Q2/2016
Pneumococcal Conjugate Vaccine					Q2/2016
Pneumococcal Polysaccharide Vaccine					2016
HIB Vaccine					Q2/2017
DTaP Vaccine					Q2/2017
HepB Vaccine					Q2/2017
Rotavirus Vaccine					Q3/2017
CA16 Vaccine					Q3/2017
Varicella Vaccine					Q2/2016

Areas of Interest for Collaboration

- Oversea distribution
- R&D cooperation
- International business
- FDA registration for vaccines
- Adjuvant technology
- Micro-carrier technology
- Novel vaccine technology

Contact Details

Name of contact person : **Ms. Helen Yang**

Address : **39 Shangdixi Road, Haidian District**

Phone : **+86 10 82799871**

City : **Beiling**

Mobile :

State : **Beijing**

Fax : **+86 10 62963661**

Location : **P.R. China**

email : **info@sinovac.com**

Postal code: **100085**

Website: **www.sinovac.com**



Name of the company : **SK Chemicals (Life Science Biz division)**

Head of Institution : **Chang Geun Kim** (CEO and Vice Chairman)
In Serk Lee (Head of Life Science Business)

Established : **1969**

Location : **Republic of Korea**

Overview of the company

SK Chemicals is a member of SK Group, the third largest company group in Korea. Since founded in 1969, it has become one of the leading competitors in the Korean vaccine market.

In 2002, SK Chemicals acquired Dongshin Pharma, a pharmaceutical company specializing in vaccines products, becoming the No. 1 vaccine company in Korea.

SK Chemicals has been particularly active in the field of vaccines in the recent years. SK Chemicals has constructed a new GMP-compliant vaccine manufacturing facility utilizing single-use, eco-friendly system in Andong, Korea in 2011 to produce vaccines developed by the company, under the joint partnership with the Korean Government. The new facility has an annual production capacity of 150 million doses and will serve as a production base for various vaccine products for both the domestic and the global market.



At the end of 2014, SK Chemicals received approval of "SkyCellflu", its new seasonal influenza vaccine manufactured with cell culture technology. SkyCellflu is a third cell-culture-based seasonal influenza vaccine product to be approved for market in the world.

SK Chemicals also puts strong weight on R&D. There are various vaccine current within the company's pipeline, notably the pneumococcal conjugate vaccine. SK Chemicals has also engaged in various R&D partnerships with renowned organizations in its efforts to develop vaccines that are much needed in the world.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
SK Td vaccine	Adsorbed tetanus-diphtheria combined toxoid for adult	Prefilled syringe	0.5ml
SK DPT-3 vaccine	Diphtheria, Tetanus and Pertussis vaccine	Prefilled syringe	0.5ml
SK influenza 10 vaccine	Egg based seasonal flu vaccine	Prefilled syringe	0.25/0.5ml
SK influenza IX vaccine	Egg based seasonal flu vaccine	Prefilled syringe	0.25/0.5ml
SK influenza	Egg based seasonal flu vaccine	Prefilled syringe	0.25/0.5ml
Hepamun prefilled	Recombinant DNA Hepatitis B vaccine	Prefilled syringe	0.5/1 ml
FirstHib	Haemophilus influenzae type b conjugated vaccine	Prefilled syringe	0.5ml
SKYCellflu	Cell-culture-based seasonal flu vaccine	Prefilled syringe	0.25/0.5ml
Others			

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Varicella vaccine					2016
Pneumococcal Conjugate Vaccine					2017
Typhoid Conjugate Vaccine					
Others					

Areas of Interest for Collaboration

- Co-development of new vaccines
- Global marketing partnership/distributorship for cell culture influenza vaccines and varicella vaccines
- Licensing-in / out of vaccine products & platform technology

Contact Details

Name of contact person	: Dr. Hun Kim	Phone	: +82 2 – 2008 – 2008 (Global Business Development Team)
Address	: 686 Sampyeong-dong, Bundang-gu	Mobile	:
City	: Seongnam-si	Fax	: +82 2-2008-2959
State	: Gyeonggi-do	email	: lifescience_global@sk.com
Location	: Republic of Korea	Website	: www.skchemicals.com/eng/main/main.asp
Postal code	: 463-400		



Name of the company : **The Biovac Institute**
Head of Institution : **Dr Morena Makhoana**
Established : **2003**
Location : **South Africa**

Overview of the company

The Biovac Institute (Biovac) is a Public Private Partnership between the South African government and a private consortium. It was formed in 2003 to re-establish domestic manufacture of human vaccines, and, ultimately, to enable regional response to vaccine-preventable diseases and regional epidemics.

Biovac is the largest distributor of vaccines in South Africa, and imports, labels, packages and distributes vaccines for the South African public sector. Biovac also imports and distributes vaccines to Southern African Development Community (SADC) countries.



It is Biovac's vision is to be a Centre of Excellence rooted in Africa for the development and manufacture of affordable quality vaccines for Africa and the developing world.

In its short history, Biovac has been able to develop capacity and know-how in conjugate vaccines. The established technology platform includes bacterial fermentation, polysaccharide purification, conjugation and the associated analytical methods. Product-development partnerships are in place with a number of international agencies.

Biovac has invested extensively over the last few years in new vaccine manufacturing and testing facilities. Inward technology transfers are under way with a number of global vaccine-manufacturer partners for local manufacture.

Biovac is the only manufacturer of human vaccines in southern Africa. It is based in Cape Town, South Africa.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
	Hepatitis B	Vial	0.5, 1.0, 5 ml
	Diluent for BCG vaccine	Vial	1ml
	Seasonal influenza vaccine	Vial or prefilled syringe	0.5ml
	Hexavalent vaccine	Vial	0.5ml

Future Product Pipe Line

- Hib (bulk): Biovac has developed its own *Haemophilus influenza* type b vaccine technology and has successfully concluded out-licensing deals
- Influenza (Pandemic)
- Further contract formulation/filling/finishing – various technology transfer products

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

Biovac welcomes the opportunity to evaluate collaborative partnerships related to the development and manufacture of vaccines and other biological products relevant to Africa and other developing countries.

- Inward technology transfers on products relevant to Africa, particularly bacterial and conjugate vaccines.
- Collaborations on conjugate-vaccine product development
- Contract production of bulk antigen – pilot and full-scale GMP
- Sourcing finished products for the local and regional market

Contact Details

Name of contact person : Patrick Tippoo

Address : 15 Alexandra Road, Pinelands

Phone : +27 21 514 5000

City : Cape Town

Mobile :

State : Western Cape

Fax : + 27 86 518 1127

Location : South Africa

email : patrick@biovacinstitute.co.za

Postal code: 7405

Website: www.biovac.co.za



Name of the company : **The Center for Genetic Engineering and Biotechnology**

Head of Institution : **Dr. Luis Herrera Martínez**. Director General

Established : **1986**

Country : **Cuba**

Overview of the company

The Center for Genetic Engineering and Biotechnology (CIGB) since 1986 has become one of the most important research-production facilities at the "Western Havana Bio-Cluster", equipped and staffed to close the cycle from biological research, which means from biotech product and process development, to production, registering, and commercialization. The CIGB has 20 years of experience in the production of recombinant biopharmaceutical molecules such as interferon, Hepatitis B vaccine, Synthetic Haemophilus influenzae type b vaccine, Tetra- and Penta-valent Combined vaccines, streptokinase, epidermal growth factor formulated in different forms, monoclonal antibodies and other products, which are already producing a positive impact on public health in Cuba and a positive cash flow from sales to more than 50 countries.

The CIGB with about 550 scientists and engineers work in more than 50 research and development projects, which involve new vaccines, therapeutic recombinant proteins and peptides, therapeutic monoclonal antibody and diagnostic systems. CIGB project/product portfolio is covered by more than 70 patent applications and manufacture of those arriving into production stage take place under the most stringent GMP conditions leading into international recognition by different authorities.

CIGB is open to implement a coordinated and targeted alliance-building policy, in order to speed up projects, to complement our capacities with those of our new partners, and to open new channels to the most sophisticated markets.

A component of that policy is to anticipate negotiation time and to start alliance building earlier in the product's life cycle. Thus, immersed in this movement, you will find in this document general data about the institution and summaries of eleven projects, which we considered most attractive for negotiation with your organization. However, while the mail proposed focus is set within these propositions, discussions can be opened around other projects of mutual interest as well.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Heberbiovac HB	HB Vaccine	Vial (liquid)	Pediatric and adult doses, single and multidose
Quimi- Hib	Hib Vaccine	Vial (liquid)	Pediatric, single dose
Trivac HB	Tetavalent Vaccine (DPT-HB)	Vial (liquid)	Pediatric and adult doses, single and multidose
Heberpenta L	Pentavalent Vaccine (DPT-HB-Hib). Fully liquid in one vial	Vial (liquid)	Pentavalent Vaccine (DPT-HB+Hib)
Heberon	Interferon's	Vial (liquid & freeze dried)	Several presentations
Hebekinasa	Streptokinase	Vial (freeze dried)	Several presentations
Heberprot-P	Heberprot-P® is a novel and unique medicine indicated for diabetic foot ulcer treatment (DFU). This innovative product contains epithermal growth factor (EGF) as active pharmaceutical ingredient (APhI) to be applied by intra-lesional infiltration directly in the wound site	Vial (freeze dried)	25 and 75 mcg/vial

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Heberprot - P					
HBV vaccine (NASVAC)					
HCV vaccine (CIGB - 230)					
CIGB - 500 (Cytoprotective Agent)					
CEA recombinant antibody fragment (CIGB - M3)					
HPV vaccine					
Prostate cancer vaccine					
CIGB - 370 (Anti- tumor agent)					
CIGB - 166 (anti- VEGF antibody)					
CIGB _ 247 (VEGF vaccine)					
CIGB - 552 (anti -tumor peptide)					
Dengue vaccine					
Dengue anti-viral molecules					
CIGB - 845 (neure-protective agent)					
Peptide for Rheumatoid Arthritis					

Areas of Interest for Collaboration

- Business Strategy for International Partnership in R&D CIGB's Projects
- CIGB is open to implement a coordinated and targeted alliance-building policy, in order to speed up projects, to complement our capacities with those of our new partners, and to open new channels to the most sophisticated markets

Contact Details

Name of contact person : **Dr. Luis Herrera Martinez**

Address : **ave 31. entre 158 y 190. Cubanacan Playa**

Phone : **+53 7 271 6013**
+53 7 271 6022

City : **Havana**

Mobile :

State : **Havana City**

Fax : **+53 7 33 6008**

Country: **Cuba**

email : **luis.herrera@cigb.edu.cu**

Postal code: **PO Box 6162**

Website: **www.cigb.edu.cu**



Name of the company : **The Company for Vaccine and Biological Production No.1 (VABIOTECH)**

Head of Institution : **1 Yersin Street, Hanoi, Vietnam**

Established : **2000**

Location : **Vietnam**

Overview of the company

The Company for Vaccine and Biological Production No.1 is a State-Owned Company which used to belong to The National Institute of Hygiene and Epidemiology (NIHE), Hanoi-Vietnam. From June 2010, VABIOTECH has been transformed into a State Owned One Member Limited Company

VABIOTECH is one of the leading companies in Vietnam in manufacturing, trading, researching and developing a wide range of vaccines and biologicals for human use, analyzing samples of new developed vaccines and biological products, diagnostic kits, therapeutic products, pharmaceuticals; cosmetics, nutrition foods, providing healthcare services... Being the biggest vaccine



manufacturer and supplier for the National Expanded Program on Immunization in Vietnam with GMP-qualified facilities, VABIOTECH is proud of its contribution to prevent, eliminate and gradually eradicate dangerous infectious diseases in order to improve children's health in Vietnam. Currently, VABIOTECH produces 4 vaccines: Hepatitis B, Hepatitis A, Japanese Encephalitis, Oral cholera and a series of diagnosis kits for detection of HBsAg, anti-HBs, anti-HCV and anti-HIV. Besides, VABIOTECH also imports and provides some other vaccines and biological products to meet the market's demand such as: Mumps, Rubella, Meningococcal and Varicella. VABIOTECH is highly committed to provide its best products at favorable price in order to protect Vietnamese people's health and well-being.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hepatitis A Vaccine	Vaccine is a suspension containing inactivated hepatitis A virus (HM 175 hepatitis A strain) absorbed onto aluminum hydroxide.	vial	1.0
Hepatitis B vaccine	It is a non-infectious, inactivated recombinant subunit viral vaccine derived from HBsAg produced in yeast cells using recombinant DNA technology. It is a whitish turbid liquid which is produced by culture of genetically engineered yeast cells which carry the relevant gene of HBsAg, purified and inactivated by several physico-chemical steps such as ultra centrifugation, column chromatography and formaldehyde treatment.	vial	0.5/1.0
Japanese Encephalitis vaccine	The vaccine is produced by VABIOTECH upon technology transfer from BIKEN Institute – Japan, use Japanese encephalitis virus Nakayama strain. This is an inactivated, purified vaccine derived from mouse brain.	vial	1.0/5.0
Cholera vaccine	The vaccine is used against Cholera. The vaccine is produced from Cholera bacteria, consisting of V Cholerae Classical biotype, ELTor and O 139.	vial	7.5

Future Product Pipe Line

- H₃N₂ influenza vaccine (Primary Monkey kidney cell base)
- Hib conjugate vaccine
- Rabies vaccine (vero cell base)
- Japanese Encephalitis vaccine (vero cell base)
- Enterovirus 71 vaccine (EV71)
- S. typhoid Vi conjugate vaccine
- Hepatitis A vaccine (vero cell base)

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
H ₃ N ₂ influenza vaccine					I/2014
Hib conjugate vaccine					I/2016
Rabies vaccine					I/2016
Japanese Encephalitis vaccine					I/2017
Ev71 vaccine					I/2016
S. typhoid Vi conjugate vaccine					I/2016
Hepatitis A vaccine					I/2016

Areas of Interest for Collaboration

- Technology transfer
- Filling and secondary packadging
- Register; collaborate in doing clinical trial, import and market vaccines and biological products in Vietnam's market.
- Export VABIOTECH's products
- Research, develop and commercialize new generation vaccines in Vietnam.

Contact Details

Name of contact person : Do Tuan Dat, M.D., Ph.D.

Address : 1, Yersin Street

Phone : + 84 4 39729166

City : Hanoi

Mobile : + 84 912007549

State :

Fax : + 84 4 39717711

Country: Vietnam

email : dotuandat@vabiotech.com.vn

Postal code: 10000

Website: http://www.vabiotech.com.vn





Name of the company : **The Government Pharmaceutical Organization**

Head of Institution : **Dr. Suwach Siasiriwattana MD. Managing Director.**

Established : **5th August 1966**

Location : **Thailand**

Overview of the company

The Government Pharmaceutical Organization (GPO) of Thailand is a state enterprise under Ministry of Public Health. It was founded in the year 1966 by merging of a pharmaceutical manufacturing plant (founded in 1939) and Pharmaceutical Department (founded in 1901) according to the GPO Act of 1966. The annual revenue of fiscal year 2012 (Oct 2011-Sep 2012) is approx. 400 mUSD. The total pharmaceutical product items are more than 300. The total staff is about 2,700.

The main responsibility of GPO is to produce medicines and pharmaceutical products to serve the national health security system and other medicine supplies. Biological Product Department of GPO is, one of the Production Clusters, responsible for production of vaccines and antisera. At present, staff under this department is about 180. Our current products are JE (MB) vaccine, antiserum of



tetanus and snake venoms. The coming vaccines of dT, TT, DTP DTP-HB and influenza vaccines are under development. The development of influenza vaccine has been supported by WHO and Thai Government including domestic and international networks. The H1N1 2009 PLAIV was registered for pandemic purpose in July 2011. The new strain H5N2 PLAIV is now completed clinical study Phase II and ongoing to submit for registration for pandemic use. The seasonal IIV is being scaled up from pilot scale to industrial scale with technical assistance from KAKETSUKEN, Japan.

The industrial influenza vaccine plant in Saraburi province (120 Km away from Bangkok) is under construction with the support from the government and this will be the new factory for biological products in the future.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5 / 1.0 / 5.0 / 10.0 ml
Japanese Encephalitis vaccine	Inactivated Japanese Encephalitis vaccine, Beijing strain	Vial	0.5 ml and 5.0 ml
TAT	Tetanus Antitoxin	Ampoule / Vial	1ml / 2ml
Antisnake venom	Anti Cobra, Anti Malayan Pit Viper, Anti Russell's Viper	Ampoule	10ml

Future Product Pipe Line

- Inactivated Influenza vaccine
- Live attenuated Influenza vaccine
- DTP-Hepatitis B vaccine
- dT vaccine
- Tetanus vaccine
- Cell based JE

Product Name	Pre Clinical		Clinical		Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Development of other vaccines and biopharmaceutical products
- Technology transfer
- Research Collaboration

Contact Details

Name of contact person : **Mr. Sit Thirapakpoomanunt**

Address : **75/1 Rama 6 Road, Ratchthewi, Bangkok 10400**

City : **Bangkok**

State :

Location : **Thailand**

Postal code:

Phone : **+662 203 8500**

Mobile : **+668 5155 3304**

Fax : **+662 644 8851**

email : **sit.thira@gpo.or.th**

Website: **www.gpo.or.th**



Name of the company : **The Holding company for Biological products and Vaccines (VACSERA)**

Head of Institution : **Dr. Olfat Mustafa Ghourab**

Established : **1881, The oldest manufacturer of vaccines in Africa & the Middle East. It turned into a governmental organization by 1970s then into a holding company in 2002.**

Location : **Egypt**

Overview of the company

The Holding Company for Biological Products & Vaccines (VACSERA) is the only producer of vaccines & sera in Egypt and has one of the main blood banks.

VACSERA's long journey of disease prevention & vaccine production started in 1881 as a small laboratory established by the government to produce vaccines, and the first success story was the production of smallpox vaccine for the first time in Egypt by 1893.

In July 2002, VACSERA became a state owned holding company with three affiliated companies:

1. EGYVAC : The Egyptian Company for Production of Vaccines, Sera and Drugs.

2. EGYBLOOD : The Egyptian Company for Blood Transfusion Services.

3. EGYVET : The Egyptian Company for Drugs & Veterinary Vaccines.

Ever since, VACSERA is dedicated to fulfill Egypt's strategic public health needs from vaccines, sera & biological products.

We are also committed to export vaccines to the public sector of developing countries especially Africa and Gulf area at preferential price.

As a leading company in the field of biological products & vaccines, we are devoted to excel all over our scope of work and to carry out continuous improvement program aiming to comply with the international standards. We strive to achieve this goal with an honest commitment towards our customers, employees, society, country & the whole environment as well.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
I. Vaccines			
Toxovac	Adsorbed Tetanus Toxoid vaccine	Vial / amp	0.5 ml & 5 ml
DT vaccine (for pediatric use)	Diphtheria & Tetanus Toxoids	Vial / amp	0.5 ml & 5 ml
DT vaccine (for Adult use)	Diphtheria & Tetanus Toxoids	Vial / amp	0.5 ml & 5 ml
DTP vaccine	Diphtheria & Tetanus Toxoids & inactivated Bordetella pertussis	Vial / amp	0.5 ml & 5 ml
Cholera vaccine	Formaldehyde Killed Vibrio cholera	Vial / amp	0.5 ml & 10 ml
Typhoid vaccine	Formaldehyde Killed Salmonella typhi	Vial / amp	0.5 ml & 10 ml
Mixvac (Typhoid / tetanus vaccine)	killed Salmonella typhi	Vial / amp	10 ml
Meningococcal AC Vaccine	Purified polysaccharide From Neisseria meningitidis of types A & C	vial	10 ml & 25 ml
Speeda Rabies vaccine for human use	Freeze dried rabies vaccine vero cell	vial	0.5 ml
II. Sera			
Polyvalent anti - scorpion serum	Anti - scorpion serum (liquid/ lyophilized)	amp	1 ml
Snake venom antiserum polyvalent (liquid / lyophilized)	Polyvalent anti - snake serum	Vial	10 ml
Polyvalent anti - viper venom serum (lyophilized)	Polyvalent anti - viper serum	Vial	5 ml
Tetanus antitoxin 30000 IU (therapeutic)	Tetanus antitoxin 30000 IU	Vial	10 ml
Tetanus antitoxin 1500 IU (prophylactic)	Tetanus antitoxin 1500 IU	Amp	1 ml
Tetan 3000 IU (prophylactic)	Tetanus antitoxin 3000 IU	Amp	1 ml
Diphtheria antitoxin	Diphtheria antitoxin 10000 IU	Vial	10 ml
Polyvalent anti - viper venom serum (liquid)	Polyvalent anti - viper serum	Vial	5 ml
III. Biopharmaceuticals			
Insulin- Mix VACSERA	Human insulin- Mix (100 I.U.)	vial	10 ml
BCG-T	Effective treatment for some non-invasive bladder cancers. It's given directly into the bladder (intravesical).	vial	3 ml
Abevac®	Bee venom	vial	1 ml

Future Product Pipe Line

Vaccines:

- Penta vaccine (DTPw- HB- HiB)
- Seasonal Influenza vaccine
- Rabies vaccine
- Bi-valent OPV
- Haemophilus Influenza vaccine

Veterinary Vaccines:

- Veterinary Influenza vaccine (Avian flu)

Blood derivatives:

- Human Albumin
- Factors VII, VIII & IX
- Gama-globulins.

Others:

- Retractable safety syringes.

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Technology transfer of vaccines.

Contact Details

Name of contact person	: Dr. Olfat Mustafa Ghourab-Chairman of VACSERA	
	Dr. Nabil El Beblawy-Chairman of EGYVAC	Phone : +20-2-37611111
Address	: 51, Wezaret El-Zeraa st., Agouza.	Mobile :
City	: Giza	Fax : +20-2-37609177
State	:	email : ceo@vacsera.com
		ceo@egyvac.com
Location	: Egypt	Website : www.vacsera.com
Postal code	: 12311	





Name of the company : **Vins Bioproducts Ltd.**

Head of Institution : **Mr.S.N. Daga**

Established : **1997**

Location : **India**

Overview of the company

VINS Bioproducts Ltd. is committed to manufacture and market WHO standard anti-sera immunoglobulins to the customers in India and also worldwide. Vins produces anti-sera immunoglobulins like.



- Snake venom anti-serum
- Rabies anti-serum
- Scorpion venom anti-serum
- Anti-sera for tetanus
- Diphtheria and Gas gangrene

Anti-sera manufactured by VINS are accredited by the world health organization and other international agencies and we are engaged in continuous improvement of products and processes to enhance the quality of production and cost competitiveness in order to build value for our customers. Vins Bioproducts Ltd. serves its customers globally with sales in over 60 countries. We have also expanded the business by building capabilities internally, through strategic expansions and acquisitions.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Rabies Immunoglobulin 1000 I.U. (VINRAB) - Liquid	Rabies antiviral Immunoglobulin	Vial	5ml
Rabies Immunoglobulin 1500 I.U. (VINRIG)- Liquid	Rabies antiviral Immunoglobulin	Vial	5ml
Snake Anti venom Immunoglobulin	Polyvalent Snake antivenom Immunoglobulin	Vial	Liquid :10 ml vial. Lyophilized : 10 ml vial.
I.P – Liquid/Lyophilized Snake Snake Anti venom Immunoglobulin(African 10) Liquid and Lyophilized.	Polyvalent Snake venom Antiserum (African)antivenom Immunoglobulin	Vial	Liquid :10 ml vial. Lyophilized : 20ml vial.
Snake Anti venom Immunoglobulin(Central Africa)-Lyophilized	Polyvalent Snake venom Antiserum (Central Africa)antivenom Immunoglobulin	Vial	20ml vial.
Snake Anti venom Immunoglobulin(Echis) Liquid and Lyophilized	Echisantivenom Immunoglobulin	Vial	Liquid :10 ml vial. Lyophilized : 20ml vial.
Russell's Viper Snake Anti venom Immunoglobulin (Vipernom)- Lyophilized	Russell's viper antivenom Immunoglobulin	Vial	20 ml vial
Cobra Snake Anti venom Immunoglobulin (Cobranom)- Lyophilized	Cobra antivenom Immunoglobulin	Vial	20 ml vial
Scorpion Snake Anti venom Immunoglobulin – Lyophilized	Scorpion antivenom Immunoglobulin	vial	1 ml
Tetanus Antitoxin 1000 I.U. B.P - Liquid	Used in the treatment of Tetanus caused by clostridium tetani.	Vial	1 ml
Tetanus Antitoxin 1500 I.U. - Liquid	Used in the treatment of Tetanus caused by clostridium tetani.	Vial	1 ml
Tetanus Antitoxin 1500 I.U. I.P - Liquid	Used in the treatment of Tetanus caused by clostridium tetani.	Pre filled syringe	1 ml
Diphtheria Antitoxin 10,000 I.U. B.P/ I.P - Liquid	Used in the treatment of Diphtheria caused by corenebacteriumdiphtheriae.	Vial	10 ml
Mixed gas gangrene Antitoxin 25,000 I.U. I.P/B.P - Liquid	Used in the treatment of Gas Gangrene	Vial	10 ml

Future Product Pipe Line

- Chimeric Anti gas gangrene serum
- Anti Thymocyte globulins

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Chimeric Anti gas gangrene serum		Under R & D			
Anti Thymocyte globulins					

Areas of Interest for Collaboration

- Technology transfers
- University collaboration

Contact Details

Name of contact person	: Mr.Siddarath Daga	Phone	: +91-40-23354550
Address	: 806, Essjay House, Road No.3, Banjara Hills	Mobile	: +91-9848051516
City	: Hyderabad	Fax	: +91-40 -23350410
State	: Telangana	email	: sdaga@vinsbio.in,info@vinsbio.in
Location	: India	Website	: www.vinsbio.in
Postal code	: 500034		



Name of the company : **Walvax Biotechnology Co., Ltd**
 Head of Institution : **Li Yunchun**
 Established : **2001**
 Location : **P.R. China**

Overview of the company

Walvax Biotechnology Co., Ltd. (referred to as Walvax) was founded in 2001, which is a modern biological pharmaceutical enterprise engaged in R & D, production and sales of bio-medicine products. Walvax is committed to provide safe bio-medicine (such as vaccines, blood products and so on) with excellent quality and advanced technology for domestic and foreign markets. Walvax's headquarters is located in Kunming, Yunnan Province of China. Currently, Walvax has a modern R & D center in National High-tech Zone of Kunming, and a modern vaccine production base and pilot base in High-tech Zone of Yunnan Yuxi and Jiangsu Taizhou China Medical City, respectively. Walvax's marketing network covers 30 provinces and cities of China, which includes more than 2000 counties.



In November, 2010, Walvax Biotechnology Co., Ltd. (stock name: Walvax Biotech, and stock code: 300142) listed on Shenzhen Stock Exchange. The operation income of 2014 reached 719.02 million RMB, while the net profit was 143.42 million RMB.

Walvax has successfully developed 20 vaccines, in which Haemophilus Influenzae Type b Conjugate Vaccine, Group A, C Meningococcal Polysaccharide Conjugate Vaccine Freeze Dried, Group A, C, W135 and Y Meningococcal Polysaccharide Vaccine and Group A, C Meningococcal Polysaccharide Vaccine Freeze Dried have been already marketed.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Haemophilus Influenzae Type b Conjugate Vaccine	The product officially launched into market in September 2007. This vaccine is indicated for infants from the age of 2 months to 5 years to induce the active immunization against infectious diseases caused by <i>Haemophilus influenzae</i> type b, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis etc.	Vial	0.5 ml
Haemophilus Influenzae Type b Conjugate Vaccine	In April 2010, Walvax launched a prefilled syringe dosage form of Haemophilus Influenzae Type b Conjugate Vaccine (Hib). Compared to similar products of semi-prefilled syringe dosage form, our prefilled syringe Hib vaccine need just two-step inject operation: Remove the needle shield, and inject. Since no re-dissolution and no need to pierce the vial cap, it can effectively reduce the abundant procedures and waste items in the course of injection. It also can effectively avoid contamination and keep the tip intact. So it can reduce the pain of the vaccinated children.	Pre-filled syringe	0.5 ml
Group A, C Meningococcal Polysaccharide Conjugate Vaccine, Freeze Dried	The product was on market officially in September 2009. The vaccine is indicated for infants from the age of 3 months to 5 years preventing diseases caused by Meningococcal Group A or C, such as cerebrospinal meningitis and septicemia.	Vial	0.5 ml
Group A, C Meningococcal Polysaccharide Vaccine Freeze Dried	The product was on market officially in December 2012. This product is only recommended for Children and adults over the age of 2 years. This vaccine is used to prevent disease caused by the bacteria named "Neisseria meningitidis groups A and group C".	Vial	0.5 ml
Group A, C, W135 and Y Meningococcal Polysaccharide Vaccine	The product was on market officially in December 2012. Currently, this product is only recommended for children above 2 years old and the people who are at the high risk of getting this disease to use. After vaccination, it can prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135.	Vial	1ml /vial/ lyophilized vaccine + 0.5ml / vial /diluent

Future Product Pipe Line

- 23 valent pneumococcal polysaccharide vaccine
- Diphtheria, Tetanus and acellular Pertussis Combined vaccine, Adsorbed
- Tetanus toxoidvaccine, adsorbed
- Human recombinant papillomatosis poison bivalent vaccine type (16/18) (yeast)
- Restructuring the HER2 humanized monoclonal antibodies
- Inactivated split Influenza vaccine
- Recombined (Hansenula polymorpha) Hepatitis B vaccine
- DTaP+Hib combined vaccine
- Restructuring of TNF alpha human mouse chimeric monoclonal antibody
- Recombination anti-tumor necrosis factor alpha all anthropogenic monoclonal antibodies
- 13 valent pneumococcal conjugate vaccine
- Group A, C, W135 and Y Meningococcal conjugate Vaccine
- Immunoglobulin (pH4)
- Typhoid vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
	Phase 1	Phase 2	Phase 3		
23 valent pneumococcal polysaccharide vaccine					
Diphtheria, Tetanus and acellular Pertussis Combined vaccine, Adsorbed					
Tetanus toxoidvaccine, adsorbed					
Human recombinant papillomatosis poison bivalent vaccine type (16/18) (yeast)					

Areas of Interest for Collaboration

Walvax strives to become your best collaboration partner in China. Area of collaboration includes product distributorship, licenses-in/out and manufacture support. Products for Distribution in Asia (especially Southeast Asia)

- Vaccine:
 - Inactivated Polio Vaccine (IPV), Measles-Mumps-Rubella vaccine (MMR), Varicella vaccine, Rotavirus Vaccine, Pneumococcal Vaccine
- Source Biologics from world
 - 1.Vaccine
 - 2.Blood Plasma Products
 - 3.Biologics

Contact Details

Name of contact person	: Gong Su	Phone	: +86-871 68312659
Address	: 19/F Bldg.9A, Dingyi Tiancheng Residential Quarter, No. 99Keyuan Road, High & New Tech Development Zone, Kunming, Yunnan Province, China	Mobile	: +86-15969446240
City	: Kunming	Fax	: +86-871 68312567
State	: Yunnan	email	: yfzxgs@walvax.com
Location	: P.R. China	Website	: www.walvax.com
Postal code	: 650106		





Name of the company : **Xiamen Innovax Biotech Co., Ltd.**
Head of Institution : **Mr. Steven Gao**, General Manger
Established : **2005**
Location : **P.R. China**

Overview of the company

Xiamen Innovax Biotech CO., LTD. (INNOVAX) is a leading company in the field of developing, manufacturing and marketing innovative vaccines with its headquarter and manufacture base in Xiamen, China.



In collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD), INNOVAX has established a core-platform using DNA recombinant technology to express protein in *E. coli* for vaccine production. Based on this platform, the world's first Hepatitis E Vaccine--Hecolin® has launched in China in October 2012. In addition, a Cervical Cancer Vaccine--Cecolin®, which is under clinical trial phase III and a Genital Warts Vaccine, which has started the phase I clinical trial, have been developed. Besides, a 9-valent HPV vaccine is now in application of clinical approval.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Hecolin®	Hepatitis E Vaccine (E.coli)	Pre-filled Syringe	0.5 ml

Future Product Pipe Line

- Cervical Vaccine (HPV16/18)
- Condyloma Acuminate Vaccine (HPV6/11)
- 9-valent HPV Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Cervical Vaccine (Cecolin®,HPV16/18)				2012-2018	2019
Condyloma Acuminate Vaccine (HPV6/11)			2015-2016	2016-2018	2021
9-valent HPV Vaccine		2018	2019-2020	2020-2024	2027

Areas of Interest for Collaboration

- Licensing
- Overseas distribution
- Product co-development

Contact Details

Name of contact person	: Wendy Huang	Phone	: +86-592-6536555-(8118)
Address	: No.130 Xinyuan Road, Haicang district	Mobile	: +86-13666096039
City	: Xiamen	Fax	: +86-592-6536567
State	: Fujian Province	email	: wendy_huang@innovax.cn
Location	: P.R. China	Website	: www.innovax.cn
Postal code	: 361022		

List of Member Organizations

1.	Arab Company for Pharmaceutical Products (Arabio)	Saudi Arabia	1
2.	Beijing Minhai Biotechnology Co., Ltd.	P.R. China	3
3.	Beijing Tiantan Biological Products Co., Ltd.	P.R. China	5
4.	Bharat Biotech International Limited.	India	7
5.	Biological E. Limited.	India	9
6.	Bio Farma	Indonesia	11
7.	Bio-Manguinhos - Institute of Technology on Immunobiologicals	Brazil	13
8.	BioNet-Asia Co., Ltd.	Thailand	15
9.	Bravo Vax Co., Ltd.	P.R. China	17
10.	Cadila Pharmaceuticals Limited.	India	19
11.	Center for Research and production of Vaccine and Biological (POLYVAC),	Vietnam	21
12.	Changchun BCHO Biotechnology Co.	P.R. China	23
13.	China National Biotec Group (CNBG)	P.R. China	25
14.	EuBiologics, Co. Ltd.	Republic of Korea	27
15.	Finlay Institute	Cuba	29
16.	Fundação Atila de Paiva	Brazil	31
17.	Green Cross Corporation	Korea	33
18.	Haffkine Bio-Pharmaceutical Corporation Limited.	India	35
19.	Incepta Vaccine Ltd.	Bangladesh	37
20.	Indian Immunologicals Limited.	India	39
21.	Institute of Vaccines and Medical Biologicals	Vietnam	41
22.	Instituto Butantan	Brazil	43
23.	Institute of Medical Biology, Chinese Academy of Medical Sciences	P.R. China	45

List of Member Organizations

24.	Laboratorios de Biológicos y Reactivos de México, S.A.de C.V.(BIRMEX)	Mexico	47
25.	LG Life Sciences Ltd.	Republic of Korea	49
26.	Liaoning Cheng Da Biotechnology Co., Ltd. (CDBIO)	P.R. China	51
27.	Medigen Vaccinology Corporation	Taiwan	53
28.	National Administration of Laboratories and Institutes of Health ANLIS "Dr. Carlos G. Malbrán"	Argentina	55
29.	National Institute of Infectious Diseases and Vaccinology	Taiwan	57
30.	Panacea Biotec Ltd.	India	59
31.	Pasteur Institute of Iran	IR of Iran	61
32.	Queen Saovabha Memorial Institute	Thailand	63
33.	Razi Vaccine & Serum Research Institute	IR of Iran	65
34.	Serum Institute of India Ltd.	India	67
35.	Sinergium Biotech S.A.	Argentina	69
36.	Sinovac Biotech Ltd.	P.R. China	71
37.	SK Chemicals (Life Science Biz division)	Republic of Korea	73
38.	The Biovac Institute	South Africa	75
39.	The Center for Genetic Engineering and Biotechnology	Cuba	77
40.	The Company for vaccine and biological production No.1 – VABIOTECH	Vietnam	79
41.	The Government Pharmaceutical Organization	Thailand	81
42.	The Holding Company for Biological Products & Vaccines (VACSERA)	Egypt	83
43.	Vins Bioproducts Ltd.	India	85
44.	Walvax Biotechnology Co., Ltd.	P.R. China	87
45.	Xiamen Innovax Biotech Co. Ltd.	P.R. China	89



DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK





India

DCVMN, 4th Floor, Gumidelli Commercial Complex, 1-10-39 to 44,
Old Airport road, Begumpet, Hyderabad-500016, India
Ph: +91 40 67043947 Fax: +91 40 67043999 Email: admin@dcmvn.org

Switzerland

DCVMN International, Route de Crassier 7, 1262-Nyon - Switzerland
Tel: +41 22 595 13 93 Fax: +41 22 595 67 00
Email: executivesecretary@dcmvn.org

www.dcmvn.org

DEVELOPING | COUNTRIES | VACCINE | MANUFACTURERS | NETWORK